VIVEKSUBBIAHVIVEK SUBBIAH9518SUBBIAH, VIVEKAssistant Professorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson1400 Holcombe BlvdHouston77030-4008TXAuthorship 1820391Authorship 1826021Authorship 1834051Authorship 1853311Authorship 1860451Authorship 1871351Authorship 1876352Authorship 1880671Authorship 1897114Authorship 1902781Authorship 1906911Authorship 1912193Authorship 193798119533369Subbiah V, Anderson P, Lazar AJ, Burdett E, Raymond K, Ludwig JACurrent treatment options in oncologyEwing's sarcoma: standard and experimental treatment options. Curr Treat Options Oncol. 2009 Apr; 10(1-2):126-40.Curr Treat Options Oncol2009-06-17T00:00:002009Ewing's sarcoma: standard and experimental treatment options.20187067Reynoso D, Subbiah V, Trent JC, Guadagnolo BA, Lazar AJ, Benjamin R, Pollock RE, Ludwig JAJournal of surgical oncologyNeoadjuvant treatment of soft-tissue sarcoma: a multimodality approach. J Surg Oncol. 2010 Mar 15; 101(4):327-33.J Surg Oncol2010-03-15T00:00:002010Neoadjuvant treatment of soft-tissue sarcoma: a multimodality approach.20220197Subbiah VThe New England journal of medicineCase 36-2009: A man with cough, hoarseness, and abnormalities on chest imaging. N Engl J Med. 2010 Mar 11; 362(10):961; author reply 961.N Engl J Med2010-03-11T00:00:002010Case 36-2009: A man with cough, hoarseness, and abnormalities on chest imaging.20811820Subbiah VJournal of cancer education : the official journal of the American Association for Cancer EducationThere are still some things money can't buy. J Cancer Educ. 2011 Jun; 26(2):395-6.J Cancer Educ2011-06-01T00:00:002011There are still some things money can't buy.20864919Subbiah V, Ludwig JAClinical advances in hematology & oncology : H&OReview: Ewing sarcoma treatment: a role for bisphosphonates? Clin Adv Hematol Oncol. 2010 Jul; 8(7):503-4.Clin Adv Hematol Oncol2010-07-01T00:00:002010Review: Ewing sarcoma treatment: a role for bisphosphonates?21809923Subbiah VJournal of palliative medicineTo ring or wring the bell? J Palliat Med. 2011 Aug; 14(8):968-9.J Palliat Med2011-08-01T00:00:002011To ring or wring the bell?24422672Subbiah V, Westin SN, Wang K, Araujo D, Wang WL, Miller VA, Ross JS, Stephens PJ, Palmer GA, Ali SMJournal of hematology & oncologyTargeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein. J Hematol Oncol. 2014 Jan 14; 7:8.J Hematol Oncol2014-01-14T00:00:002014Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein.Investigational Cancer TherapeuticsLeukemiaPalliative Care & Rehabilitation MedicineThoracic Head & Neck Medical OncologyMD AndersonJOHN VICTORHEYMACHJOHN VICTOR HEYMACH9280HEYMACH, JOHN VICTORProfessorSARINA ANNEPIHA-PAULSARINA ANNE PIHA-PAUL9343PIHA-PAUL, SARINA ANNEAssociate Professor8.820890.00874394775research areas12.56850.0236314272coauthor of602.171111.81160similar to11449selected publicationsHAGOP MKANTARJIANHAGOP M KANTARJIAN8501KANTARJIAN, HAGOP MProfessorEDUARDOBRUERAEDUARDO BRUERA8804BRUERA, EDUARDOProfessorFILIPJANKUFILIP JANKU9598JANKU, FILIPAssistant ProfessorFUNDAMERIC-BERNSTAMFUNDA MERIC-BERNSTAM8778MERIC-BERNSTAM, FUNDAProfessorDAVID SANGHYUNHONGDAVID SANGHYUN HONG9016HONG, DAVID SANGHYUNAssociate ProfessorAUNGNAINGAUNG NAING9382NAING, AUNGAssociate ProfessorAuthorship 2238701Authorship 2268751Authorship 2278901Authorship 2291201Authorship 2302271Authorship 230677117330833Subbiah V, Chanock SJPediatric blood & cancerModifiers of risk for infectious complications of cancer therapy in children: the long road ahead. Pediatr Blood Cancer. 2007 Jul; 49(1):3-5.Pediatr Blood Cancer2007-07-01T00:00:002007Modifiers of risk for infectious complications of cancer therapy in children: the long road ahead.18400110Subbiah V, Parimi PJournal of medical case reportsElevated maternal lipoprotein (a) and neonatal renal vein thrombosis: a case report. J Med Case Rep. 2008 Apr 10; 2:106.J Med Case Rep2008-04-10T00:00:002008Elevated maternal lipoprotein (a) and neonatal renal vein thrombosis: a case report.18550263Subbiah V, Viny AD, Rosenblatt S, Pohlman B, Lichtin A, Maciejewski JPExperimental hematologyOutcomes of splenectomy in T-cell large granular lymphocyte leukemia with splenomegaly and cytopenia. Exp Hematol. 2008 Sep; 36(9):1078-83.Exp Hematol2008-06-11T00:00:002008Outcomes of splenectomy in T-cell large granular lymphocyte leukemia with splenomegaly and cytopenia.21245431Subbiah V, Murthy R, Anderson PMJournal of clinical oncology : official journal of the American Society of Clinical Oncology[90Y]yttrium microspheres radioembolotherapy in desmoplastic small round cell tumor hepatic metastases. J Clin Oncol. 2011 Apr 10; 29(11):e292-4.J Clin Oncol2011-01-18T00:00:002011[90Y]yttrium microspheres radioembolotherapy in desmoplastic small round cell tumor hepatic metastases.21479975Subbiah VJournal of cancer education : the official journal of the American Association for Cancer EducationHow watching the movie Zombieland helps treatment of cancer in teenagers. J Cancer Educ. 2012 Mar; 27(1):188-91.J Cancer Educ2012-03-01T00:00:002012How watching the movie Zombieland helps treatment of cancer in teenagers.21744476Subbiah V, Varadhachary G, Herzog CE, Huh WWPediatric blood & cancerGastric adenocarcinoma in children and adolescents. Pediatr Blood Cancer. 2011 Sep; 57(3):524-7.Pediatr Blood Cancer2011-01-24T00:00:002011Gastric adenocarcinoma in children and adolescents.Authorship 25224010Authorship 2536111Authorship 2548111Authorship 2554821Authorship 2556401Authorship 2557681Authorship 2561021Authorship 2582081Authorship 2585752Authorship 2586321Authorship 2594051Authorship 2604241Authorship 2604383Authorship 2609731Authorship 2616287Authorship 262445219470940Mwanda WO, Orem J, Fu P, Banura C, Kakembo J, Onyango CA, Ness A, Reynolds S, Johnson JL, Subbiah V, Bako J, Wabinga H, Abdallah FK, Meyerson HJ, Whalen CC, Lederman MM, Black J, Ayers LW, Katongole-Mbidde E, Remick SCJournal of clinical oncology : official journal of the American Society of Clinical OncologyDose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin's lymphoma in East Africa. J Clin Oncol. 2009 Jul 20; 27(21):3480-8.J Clin Oncol2009-05-26T00:00:002009Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin's lymphoma in East Africa.20384506Subbiah VJournal of palliative medicineA friend request: to accept or decline? J Palliat Med. 2010 Apr; 13(4):465.J Palliat Med2010-04-01T00:00:002010A friend request: to accept or decline?20567010Subbiah V, Trent JC, Kurzrock RJournal of clinical oncology : official journal of the American Society of Clinical OncologyResistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors. J Clin Oncol. 2010 Aug 20; 28(24):e415.J Clin Oncol2010-06-21T00:00:002010Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors.21052545Subbiah V, Anderson PSarcomaTargeted Therapy of Ewing's Sarcoma. Sarcoma. 2011; 2011:686985.Sarcoma2010-10-31T00:00:002010Targeted Therapy of Ewing's Sarcoma.21247925Subbiah VThe American journal of hospice & palliative careHappy or unhappy christmas? Am J Hosp Palliat Care. 2011 Feb; 28(1):62.Am J Hosp Palliat Care2011-02-01T00:00:002011Happy or unhappy christmas?21494688Subbiah V, Naing A, Brown RE, Chen H, Doyle L, LoRusso P, Benjamin R, Anderson P, Kurzrock RPloS oneTargeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures. PLoS One. 2011 Apr 06; 6(4):e18424.PLoS One2011-04-06T00:00:002011Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures.21519259Subbiah V, Kurzrock RCurrent opinion in oncologyPhase 1 clinical trials for sarcomas: the cutting edge. Curr Opin Oncol. 2011 Jul; 23(4):352-60.Curr Opin Oncol2011-07-01T00:00:002011Phase 1 clinical trials for sarcomas: the cutting edge.21922648Subbiah V, Wolff J, Ketonen L, Ellezam B, Rytting MEPediatric blood & cancerAdvanced atypical teratoid/rhabdoid tumor (ATRT) treated with intensive multimodal approach shows continued response to sarcoma type salvage therapy. Pediatr Blood Cancer. 2012 May; 58(5):823-4.Pediatr Blood Cancer2011-09-15T00:00:002011Advanced atypical teratoid/rhabdoid tumor (ATRT) treated with intensive multimodal approach shows continued response to sarcoma type salvage therapy.22742646Subbiah V, Kurzrock RDiscovery medicineEwing's sarcoma: overcoming the therapeutic plateau. Discov Med. 2012 Jun; 13(73):405-15.Discov Med2012-06-01T00:00:002012Ewing's sarcoma: overcoming the therapeutic plateau.22914439Subbiah V, Brown RE, Buryanek J, Trent J, Ashkenazi A, Herbst R, Kurzrock RMolecular cancer therapeuticsTargeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist. Mol Cancer Ther. 2012 Nov; 11(11):2541-6.Mol Cancer Ther2012-08-20T00:00:002012Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist.23391555Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, Fu S, Hong DS, Piha-Paul S, Wheler JJ, Hess KR, Janku F, Falchook GS, Wolff RA, Kurzrock ROncotargetTargeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget. 2013 Jan; 4(1):156-65.Oncotarget2013-01-01T00:00:002013Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials.23895135Jardim DL, Conley A, Subbiah VOrphanet journal of rare diseasesComprehensive characterization of malignant phyllodes tumor by whole genomic and proteomic analysis: biological implications for targeted therapy opportunities. Orphanet J Rare Dis. 2013 Jul 30; 8:112.Orphanet J Rare Dis2013-07-30T00:00:002013Comprehensive characterization of malignant phyllodes tumor by whole genomic and proteomic analysis: biological implications for targeted therapy opportunities.23922674Subbiah V, Brown RE, Jiang Y, Buryanek J, Hayes-Jordan A, Kurzrock R, Anderson PMPloS oneMorphoproteomic profiling of the mammalian target of rapamycin (mTOR) signaling pathway in desmoplastic small round cell tumor (EWS/WT1), Ewing's sarcoma (EWS/FLI1) and Wilms' tumor(WT1). PLoS One. 2013; 8(7):e68985.PLoS One2013-07-29T00:00:002013Morphoproteomic profiling of the mammalian target of rapamycin (mTOR) signaling pathway in desmoplastic small round cell tumor (EWS/WT1), Ewing's sarcoma (EWS/FLI1) and Wilms' tumor(WT1).24395633Subbiah V, Brown RE, McGuire MF, Buryanek J, Janku F, Younes A, Hong DOncotargetA novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma. Oncotarget. 2014 Jan 15; 5(1):95-102.Oncotarget2014-01-15T00:00:002014A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma.24586741Jardim DL, Wheler JJ, Hess K, Tsimberidou AM, Zinner R, Janku F, Subbiah V, Naing A, Piha-Paul SA, Westin SN, Roy-Chowdhuri S, Meric-Bernstam F, Hong DSPloS oneFBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors. PLoS One. 2014; 9(2):e89388.PLoS One2014-02-19T00:00:002014FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.24924181Anderson PM, Subbiah V, Rohren EAdvances in experimental medicine and biologyBone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: samarium-153-EDTMP and radium-223. Adv Exp Med Biol. 2014; 804:291-304.Adv Exp Med Biol2014-01-01T00:00:002014Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: samarium-153-EDTMP and radium-223.Authorship 2676451Authorship 2676642Authorship 2692341Authorship 271188318166767Haddad AS, Subbiah V, Lichtin AE, Theil KS, Maciejewski JPHaematologicaHypocupremia and bone marrow failure. Haematologica. 2008 Jan; 93(1):e1-5.Haematologica2008-01-01T00:00:002008Hypocupremia and bone marrow failure.18283721Subbiah VThe New England journal of medicineChemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med. 2008 Feb 14; 358(7):743; author reply 743.N Engl J Med2008-02-14T00:00:002008Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.20383720Subbiah VSupportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerAdolescent oncology: who cares?-the new KID on the block. Support Care Cancer. 2010 Jun; 18(6):771-3.Support Care Cancer2010-04-11T00:00:002010Adolescent oncology: who cares?-the new KID on the block.23299771Janku F, Munoz J, Subbiah V, Kurzrock RThe oncologistA tale of two histiocytic disorders. Oncologist. 2013; 18(1):2-4.Oncologist2013-01-08T00:00:002013A tale of two histiocytic disorders.Authorship 2736241Authorship 275098119722276Subbiah V, Wolff JEPediatric blood & cancerRapid response to therapy of neurocutaneous melanosis with leptomeningeal melanoma. Pediatr Blood Cancer. 2010 Jan; 54(1):180-1.Pediatr Blood Cancer2010-01-01T00:00:002010Rapid response to therapy of neurocutaneous melanosis with leptomeningeal melanoma.23322213Subbiah V, Subbiah IMAnnals of hematologyKilling two birds with one stone: BRAF V600E inhibitor therapy for hairy cell leukemia and Langerhans/dendritic cell sarcoma. Ann Hematol. 2013 Aug; 92(8):1149.Ann Hematol2013-01-16T00:00:002013Killing two birds with one stone: BRAF V600E inhibitor therapy for hairy cell leukemia and Langerhans/dendritic cell sarcoma.Authorship 2820231Authorship 2894128Authorship 2896637Authorship 2904521Authorship 2905851Authorship 2905986Authorship 2910808Authorship 2912022Authorship 29154011Authorship 2915544Authorship 2917603Authorship 29350911Authorship 29351111Authorship 2936547Authorship 2938842Authorship 29402617Authorship 29424412Authorship 2944661Authorship 29457911Authorship 2953206Authorship 29542611Authorship 2955994Authorship 2957621Authorship 2967197Authorship 29778718Authorship 2989042Authorship 29944617Authorship 2997641Authorship 3003521Authorship 3020161Authorship 3021044Authorship 3040871Authorship 3047647Authorship 3048481Authorship 305032318036249Subbiah V, Ly UK, Khiyami A, O'Brien TJournal of medical case reportsTissue is the issue-sarcoidosis following ABVD chemotherapy for Hodgkin's lymphoma: a case report. J Med Case Rep. 2007 Nov 25; 1:148.J Med Case Rep2007-11-25T00:00:002007Tissue is the issue-sarcoidosis following ABVD chemotherapy for Hodgkin's lymphoma: a case report.24742823Jardim DL, de Melo Gagliato D, Falchook GS, Janku F, Zinner R, Wheler JJ, Subbiah V, Piha-Paul SA, Fu S, Murphy MB, Ajani J, Tang C, Hess K, Hamilton SR, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DSOncotargetMET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget. 2014 Apr 15; 5(7):1837-45.Oncotarget2014-04-15T00:00:002014MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit.24811890Wheler JJ, Parker BA, Lee JJ, Atkins JT, Janku F, Tsimberidou AM, Zinner R, Subbiah V, Fu S, Schwab R, Moulder S, Valero V, Schwaederle M, Yelensky R, Miller VA, Stephens MP, Meric-Bernstam F, Kurzrock ROncotargetUnique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms. Oncotarget. 2014 May 15; 5(9):2349-54.Oncotarget2014-05-15T00:00:002014Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms.25030655Subbiah VCurrent oncology reportsProspects and pitfalls of personalizing therapies for sarcomas: from children, adolescents, and young adults to the elderly. Curr Oncol Rep. 2014 Sep; 16(9):401.Curr Oncol Rep2014-09-01T00:00:002014Prospects and pitfalls of personalizing therapies for sarcomas: from children, adolescents, and young adults to the elderly.25065564de Melo Gagliato D, Jardim DL, Falchook G, Tang C, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Hess K, Roy-Chowdhuri S, Moulder S, Gonzalez-Angulo AM, Meric-Bernstam F, Hong DSClinical breast cancerAnalysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit. Clin Breast Cancer. 2014 Dec; 14(6):468-74.Clin Breast Cancer2014-06-23T00:00:002014Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit.25085632Subbiah V, Meric-Bernstam F, Mills GB, Shaw KR, Bailey AM, Rao P, Ward JF, Pagliaro LCJournal of hematology & oncologyNext generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent?) a VEGFR2/PDGFR?/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial. J Hematol Oncol. 2014 Aug 01; 7:52.J Hematol Oncol2014-08-01T00:00:002014Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent?) a VEGFR2/PDGFR?/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial.25087088Jardim DL, de Melo Gagliato D, Falchook G, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Tannir N, Corn P, Tang C, Hess K, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DSClinical genitourinary cancerMET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors. Clin Genitourin Cancer. 2015 Feb; 13(1):e19-26.Clin Genitourin Cancer2014-07-03T00:00:002014MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors.25119929Jiang Y, Subbiah V, Janku F, Ludwig JA, Naing A, Benjamin RS, Brown RE, Anderson P, Kurzrock RPloS oneNovel secondary somatic mutations in Ewing's sarcoma and desmoplastic small round cell tumors. PLoS One. 2014; 9(8):e93676.PLoS One2014-08-13T00:00:002014Novel secondary somatic mutations in Ewing's sarcoma and desmoplastic small round cell tumors.25243101Takalkar A, Adams S, Subbiah VExperimental hematology & oncologyRadium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone. Exp Hematol Oncol. 2014; 3:23.Exp Hematol Oncol2014-09-08T00:00:002014Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone.25316815Tang C, Hess K, Jardim DL, Gagliato Dde M, Tsimberidou AM, Falchook G, Fu S, Janku F, Naing A, Piha-Paul S, Subbiah V, Wheler J, Zinner RG, Kurzrock R, Ellis LM, Meric-Berstam F, Hong DSClinical cancer research : an official journal of the American Association for Cancer ResearchSynergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic. Clin Cancer Res. 2014 Dec 01; 20(23):5956-63.Clin Cancer Res2014-10-14T00:00:002014Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic.25320628Agarwal R, Koenig K, Rohren E, Subbiah VJournal of breast cancerCombined Antiangiogenic and Mammalian Target of Rapamycin Inhibitor Targeted Therapy in Metaplastic Breast Cancer Harboring a PIK3CA Mutation. J Breast Cancer. 2014 Sep; 17(3):287-90.J Breast Cancer2014-09-30T00:00:002014Combined Antiangiogenic and Mammalian Target of Rapamycin Inhibitor Targeted Therapy in Metaplastic Breast Cancer Harboring a PIK3CA Mutation.25549703Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V, Pan-Cancer Working GroupDiscovery medicineTargeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndrome. Discov Med. 2014 Dec; 18(101):323-30.Discov Med2014-12-01T00:00:002014Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndrome.25549704Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V, Pan-Cancer Working GroupDiscovery medicineTargeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome. Discov Med. 2014 Dec; 18(101):331-9.Discov Med2014-12-01T00:00:002014Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome.25572778Subbiah IM, Subbiah VFuture oncology (London, England)Exceptional responders: in search of the science behind the miracle cancer cures. Future Oncol. 2015; 11(1):1-4.Future Oncol2015-01-01T00:00:002015Exceptional responders: in search of the science behind the miracle cancer cures.25587555Corrales-Medina FF, Herzog C, Hess K, Egas-Bejar D, Hong DS, Falchook G, Anderson P, Nunez C, Huh WW, Naing A, Tsimberidou AM, Wheler J, Paul SP, Janku F, Kleinerman ES, Kurzrock R, Subbiah VOncoscienceClinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of Texas MD anderson cancer center experience. Oncoscience. 2014 Jul 27; 1(7):522-530.Oncoscience2014-07-27T00:00:002014Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of Texas MD anderson cancer center experience.25593991Vidwans SJ, Turski ML, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Subbiah V, Rodon J, Kurzrock ROncoscienceA framework for genomic biomarker actionability and its use in clinical decision making. Oncoscience. 2014; 1(10):614-623.Oncoscience2014-10-22T00:00:002014A framework for genomic biomarker actionability and its use in clinical decision making.25669829Fu S, Hou MM, Naing A, Janku F, Hess K, Zinner R, Subbiah V, Hong D, Wheler J, Piha-Paul S, Tsimberidou A, Karp D, Araujo D, Kee B, Hwu P, Wolff R, Kurzrock R, Meric-Bernstam FAnnals of oncology : official journal of the European Society for Medical OncologyPhase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. Ann Oncol. 2015 May; 26(5):1012-1018.Ann Oncol2015-02-10T00:00:002015Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.25695345Subbiah VCell cycle (Georgetown, Tex.)Fast-tracking novel drugs in pediatric oncology. Cell Cycle. 2015; 14(8):1127-8.Cell Cycle2015-01-01T00:00:002015Fast-tracking novel drugs in pediatric oncology.25695693Goswami RS, Patel KP, Singh RR, Meric-Bernstam F, Kopetz ES, Subbiah V, Alvarez RH, Davies MA, Jabbar KJ, Roy-Chowdhuri S, Lazar AJ, Medeiros LJ, Broaddus RR, Luthra R, Routbort MJClinical cancer research : an official journal of the American Association for Cancer ResearchHotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors. Clin Cancer Res. 2015 Jun 01; 21(11):2644-51.Clin Cancer Res2015-02-18T00:00:002015Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors.25725224Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V, Pan-Cancer Working GroupDiscovery medicineTargeted therapy for genetic cancer syndromes: Fanconi anemia, medullary thyroid cancer, tuberous sclerosis, and RASopathies. Discov Med. 2015 Feb; 19(103):101-8.Discov Med2015-02-01T00:00:002015Targeted therapy for genetic cancer syndromes: Fanconi anemia, medullary thyroid cancer, tuberous sclerosis, and RASopathies.25725225Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V, Pan-Cancer Working GroupDiscovery medicineTargeted therapy for genetic cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndrome. Discov Med. 2015 Feb; 19(103):109-16.Discov Med2015-02-01T00:00:002015Targeted therapy for genetic cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndrome.25859559Silva JG, Corrales-Medina FF, Maher OM, Tannir N, Huh WW, Rytting ME, Subbiah VOncoscienceClinical next generation sequencing of pediatric-type malignancies in adult patients identifies novel somatic aberrations. Oncoscience. 2015; 2(2):187-92.Oncoscience2015-02-20T00:00:002015Clinical next generation sequencing of pediatric-type malignancies in adult patients identifies novel somatic aberrations.25886034Goldstein J, Patel AB, Curry JL, Subbiah V, Piha-Paul SBMC dermatologyPhotoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: a case report. BMC Dermatol. 2015 Feb 13; 15:2.BMC Dermatol2015-02-13T00:00:002015Photoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: a case report.25902899Rodrigues HV, Ke D, Lim J, Stephen B, Bellido J, Janku F, Zinner R, Tsimberidou A, Hong D, Piha-Paul S, Fu S, Naing A, Subbiah V, Karp D, Falchook G, Kurzrock R, Wheler JInvestigational new drugsPhase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. Invest New Drugs. 2015 Jun; 33(3):700-9.Invest New Drugs2015-04-24T00:00:002015Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.25982012Subbiah V, Berry J, Roxas M, Guha-Thakurta N, Subbiah IM, Ali SM, McMahon C, Miller V, Cascone T, Pai S, Tang Z, Heymach JVLung cancer (Amsterdam, Netherlands)Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases. Lung Cancer. 2015 Jul; 89(1):76-9.Lung Cancer2015-04-22T00:00:002015Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.26015395Boland GM, Piha-Paul SA, Subbiah V, Routbort M, Herbrich SM, Baggerly K, Patel KP, Brusco L, Horombe C, Naing A, Fu S, Hong DS, Janku F, Johnson A, Broaddus R, Luthra R, Shaw K, Mendelsohn J, Mills GB, Meric-Bernstam FOncotargetClinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget. 2015 Aug 21; 6(24):20099-110.Oncotarget2015-08-21T00:00:002015Clinical next generation sequencing to identify actionable aberrations in a phase I program.26062823Subbiah V, McMahon C, Patel S, Zinner R, Silva EG, Elvin JA, Subbiah IM, Ohaji C, Ganeshan DM, Anand D, Levenback CF, Berry J, Brennan T, Chmielecki J, Chalmers ZR, Mayfield J, Miller VA, Stephens PJ, Ross JS, Ali SMJournal of hematology & oncologySTUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion. J Hematol Oncol. 2015 Jun 11; 8:66.J Hematol Oncol2015-06-11T00:00:002015STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion.26164085Subbiah IM, Falchook GS, Kaseb AO, Hess KR, Tsimberidou AM, Fu S, Subbiah V, Hong DS, Naing A, Piha-Paul SA, Akmal O, Janku F, Kurzrock ROncotargetExploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. Oncotarget. 2015 Sep 29; 6(29):28453-62.Oncotarget2015-09-29T00:00:002015Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials.26181034Subbiah V, Anderson P, Rohren EJAMA oncologyAlpha Emitter Radium 223 in High-Risk Osteosarcoma: First Clinical Evidence of Response and Blood-Brain Barrier Penetration. JAMA Oncol. 2015 May; 1(2):253-5.JAMA Oncol2015-05-01T00:00:002015Alpha Emitter Radium 223 in High-Risk Osteosarcoma: First Clinical Evidence of Response and Blood-Brain Barrier Penetration.26287849Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, Wolf J, Raje NS, Diamond EL, Hollebecque A, Gervais R, Elez-Fernandez ME, Italiano A, Hofheinz RD, Hidalgo M, Chan E, Schuler M, Lasserre SF, Makrutzki M, Sirzen F, Veronese ML, Tabernero J, Baselga JThe New England journal of medicineVemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med. 2015 Aug 20; 373(8):726-36.N Engl J Med2015-08-20T00:00:002015Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.26328274Subbiah V, Bupathi M, Kato S, Livingston A, Slopis J, Anderson PM, Hong DSOncoscienceClinical next-generation sequencing reveals aggressive cancer biology in adolescent and young adult patients. Oncoscience. 2015; 2(7):646-58.Oncoscience2015-07-08T00:00:002015Clinical next-generation sequencing reveals aggressive cancer biology in adolescent and young adult patients.26330075Janku F, Claes B, Huang HJ, Falchook GS, Devogelaere B, Kockx M, Bempt IV, Reijans M, Naing A, Fu S, Piha-Paul SA, Hong DS, Holley VR, Tsimberidou AM, Stepanek VM, Patel SP, Kopetz ES, Subbiah V, Wheler JJ, Zinner RG, Karp DD, Luthra R, Roy-Chowdhuri S, Sablon E, Meric-Bernstam F, Maertens G, Kurzrock ROncotargetBRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget. 2015 Sep 29; 6(29):26886-94.Oncotarget2015-09-29T00:00:002015BRAF mutation testing with a rapid, fully integrated molecular diagnostics system.26479420Al-Rohil RN, Tarasen AJ, Carlson JA, Wang K, Johnson A, Yelensky R, Lipson D, Elvin JA, Vergilio JA, Ali SM, Suh J, Miller VA, Stephens PJ, Ganesan P, Janku F, Karp DD, Subbiah V, Mihm MC, Ross JSCancerEvaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies. Cancer. 2016 Jan 15; 122(2):249-57.Cancer2015-10-19T00:00:002015Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies.26510912Subbiah V, Wagner MJ, McGuire MF, Sarwari NM, Devarajan E, Lewis VO, Westin S, Kato S, Brown RE, Anderson POncotargetPersonalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine. Oncotarget. 2015 Dec 01; 6(38):40642-54.Oncotarget2015-12-01T00:00:002015Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine.26562409Subbiah VJAMA oncologyCognitive Changes During Chemotherapy. JAMA Oncol. 2015 Dec; 1(9):1353.JAMA Oncol2015-12-01T00:00:002015Cognitive Changes During Chemotherapy.26581701Takalkar A, Paryani B, Adams S, Subbiah VBMJ case reportsRadium-223 dichloride therapy in breast cancer with osseous metastases. BMJ Case Rep. 2015 Nov 18; 2015.BMJ Case Rep2015-11-18T00:00:002015Radium-223 dichloride therapy in breast cancer with osseous metastases.74Professor10Assistant Professor14Associate Professor27014780Khawaja MR, Nick AM, Madhusudanannair V, Fu S, Hong D, McQuinn LM, Ng CS, Piha-Paul SA, Janku F, Subbiah V, Tsimberidou A, Karp D, Meric-Bernstam F, Lu KH, Naing ACancer chemotherapy and pharmacologyPhase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. Cancer Chemother Pharmacol. 2016 05; 77(5):973-7.Cancer Chemother Pharmacol2016-03-24T00:00:002016Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers.27207774Janku F, Huang HJ, Claes B, Falchook GS, Fu S, Hong D, Ramzanali NM, Nitti G, Cabrilo G, Tsimberidou AM, Naing A, Piha-Paul SA, Wheler JJ, Karp DD, Holley VR, Zinner RG, Subbiah V, Luthra R, Kopetz S, Overman MJ, Kee BK, Patel S, Devogelaere B, Sablon E, Maertens G, Mills GB, Kurzrock R, Meric-Bernstam FMolecular cancer therapeuticsBRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. Mol Cancer Ther. 2016 06; 15(6):1397-404.Mol Cancer Ther2016-05-20T00:00:002016BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System.27231570Fu S, Shi N, Wheler J, Naing A, Janku F, Piha-Paul S, Gong J, Hong D, Tsimberidou A, Zinner R, Subbiah V, Hou MM, Ramirez P, Ramondetta L, Lu K, Meric-Bernstam FGynecologic oncology research and practiceCharacteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience. Gynecol Oncol Res Pract. 2015; 2:10.Gynecol Oncol Res Pract2015-11-14T00:00:002015Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience.Authorship 373760719653292Subbiah V, Huff V, Wolff JE, Ketonen L, Lang FF, Stewart J, Langford L, Herzog CEPediatric blood & cancerBilateral gonadoblastoma with dysgerminoma and pilocytic astrocytoma with WT1 GT-IVS9 mutation: A 46 XY phenotypic female with Frasier syndrome. Pediatr Blood Cancer. 2009 Dec 15; 53(7):1349-51.Pediatr Blood Cancer2009-12-15T00:00:002009Bilateral gonadoblastoma with dysgerminoma and pilocytic astrocytoma with WT1 GT-IVS9 mutation: A 46 XY phenotypic female with Frasier syndrome.20168252Subbiah V, Ketonen L, Bruner JM, Nunez R, Weinberg J, Wolff JEJournal of pediatric hematology/oncology99mTc-sestamibi scan differentiates tumor from other contrast enhancing tissue in choroid plexus tumors. J Pediatr Hematol Oncol. 2010 Mar; 32(2):160-2.J Pediatr Hematol Oncol2010-03-01T00:00:00201099mTc-sestamibi scan differentiates tumor from other contrast enhancing tissue in choroid plexus tumors.22203760Subbiah V, Slopis J, Hong DS, Ketonen LM, Hamilton J, McCutcheon IE, Kurzrock RJournal of clinical oncology : official journal of the American Society of Clinical OncologyTreatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside. J Clin Oncol. 2012 Feb 10; 30(5):e64-8.J Clin Oncol2011-12-27T00:00:002011Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside.Authorship 841191Authorship 841972Authorship 842585Authorship 842872Authorship 843074Authorship 843702Authorship 844590Authorship 845047Authorship 845769Authorship 846201Authorship 846445Authorship 846557Authorship 848218Authorship 849356Authorship 849394Authorship 849543Authorship 849990Authorship 850010Authorship 852715Authorship 852917Authorship 853882Authorship 854742Authorship 854895Authorship 855136Authorship 855526Authorship 856189Authorship 856922Authorship 857119Authorship 859227Authorship 860047Authorship 860683Authorship 860887Authorship 860979Authorship 862110Authorship 862907Authorship 863199Authorship 866478Authorship 866890Authorship 867723Authorship 867919Authorship 868090Targets by organ site. Targets by organ siteJournal of Breast CancerCombined antiangiogenic and mammalian target of rapamycin inhibitor targeted therapy in metaplastic breast cancer harboring a PIK3CA mutation. Journal of Breast Cancer. 17:287-290.Combined antiangiogenic and mammalian target of rapamycin inhibitor targeted therapy in metaplastic breast cancer harboring a PIK3CA mutationMolecular Cancer TherapeuticsTP53 alterations correlate with response to VEGF/VEGFR inhibitors. Molecular Cancer Therapeutics. 15:2475-2485.TP53 alterations correlate with response to VEGF/VEGFR inhibitorsOncotargetAdvanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. Oncotarget. 7:23227-23238.Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimusOncology (Switzerland)Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion. Oncology (Switzerland). 348-353.Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 FusionOncoscienceClinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults. Oncoscience. 1:522-530.Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adultsOncology (Switzerland)Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit. Oncology (Switzerland). Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient UnitCell CycleFast-tracking novel drugs in pediatric oncology. Cell Cycle. 14:1127-1128.Fast-tracking novel drugs in pediatric oncologyExperimental Hematology and OncologyRadium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone. Experimental Hematology and Oncology. 3.Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to boneJournal of Hematology and OncologySTUMP un"stumped". Journal of Hematology and Oncology. 8.STUMP un"stumped"European Journal of Internal MedicineHeadache in a patient with renal cell carcinoma. European Journal of Internal Medicine. Headache in a patient with renal cell carcinomaTargets by organ site. Targets by organ siteMolecular Cancer TherapeuticsBRAF Mutation testing in cell-free DNA from the plasma of patients with advanced cancers using a rapid, automated molecular diagnostics system. Molecular Cancer Therapeutics. 15:1397-1404.BRAF Mutation testing in cell-free DNA from the plasma of patients with advanced cancers using a rapid, automated molecular diagnostics systemClinical Cancer ResearchHotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors. Clinical Cancer Research. 21:2644-2651.Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumorsBMC CancerRetreatment with anti-EGFR based therapies in metastatic colorectal cancer. BMC Cancer. 15.Retreatment with anti-EGFR based therapies in metastatic colorectal cancerCancer ResearchCancer therapy directed by comprehensive genomic profiling. Cancer Research. 76:3690-3701.Cancer therapy directed by comprehensive genomic profilingTargets by organ site. Targets by organ siteClinical Genitourinary CancerAntitumor Response to Combined Antiangiogenic and Cytotoxic Chemotherapy in Recurrent Metastatic Chromophobe Renal Cell Carcinoma. Clinical Genitourinary Cancer. 14:e187-e193.Antitumor Response to Combined Antiangiogenic and Cytotoxic Chemotherapy in Recurrent Metastatic Chromophobe Renal Cell CarcinomaCancer DiscoveryPhase IB study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAF<sup>V600E</sup> mutation. Cancer Discovery. 6:1352-1365.Phase IB study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAF<sup>V600E</sup> mutationOncotargetPhase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget. 7:67521-67531.Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancyOncoscienceA framework for genomic biomarker actionability and its use in clinical decision making. Oncoscience. 1:614-623.A framework for genomic biomarker actionability and its use in clinical decision makingCancerSleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials. Cancer. 122:3401-3409.Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trialsOncoscienceClinical next-generation sequencing reveals aggressive cancer biology in adolescent and young adult patients. Oncoscience. 2:646-652.Clinical next-generation sequencing reveals aggressive cancer biology in adolescent and young adult patientsAnnals of OncologyIncidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Annals of Oncology. 27:795-800.Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocolOncotargetExploring response signals and targets in aggressive unresectable hepatocellular carcinoma. Oncotarget. 6:28453-28462.Exploring response signals and targets in aggressive unresectable hepatocellular carcinomaOncoscienceTheranostic profiling for actionable aberrations in advanced high risk osteosarcoma with aggressive biology reveals high molecular diversity. Oncoscience. 1:167-179.Theranostic profiling for actionable aberrations in advanced high risk osteosarcoma with aggressive biology reveals high molecular diversityCancer Chemotherapy and PharmacologyPhase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. Cancer Chemotherapy and Pharmacology. 1-5.Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancersScientific ReportsEvaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. Scientific Reports. 6.Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved TherapiesTargets by organ site. Targets by organ siteOncotargetBRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget. 6:26886-26894.BRAF mutation testing with a rapid, fully integrated molecular diagnostics systemProceedings of the National Academy of Sciences of the United States of AmericaClinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 113:E1419-E1420.Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancerOncotargetValidation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. Oncotarget. 7:64421-64430.Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trialsOncotargetClinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget. 6:20099-20110.Clinical next generation sequencing to identify actionable aberrations in a phase I programOncoscienceClinical next generation sequencing of pediatric-type malignancies in adult patients identifies novel somatic aberrations. Oncoscience. 2:187-192.Clinical next generation sequencing of pediatric-type malignancies in adult patients identifies novel somatic aberrationsOncotargetPersonalized comprehensive molecular profiling of high risk osteosarcoma. Oncotarget. 6:40642-40654.Personalized comprehensive molecular profiling of high risk osteosarcomaBMC DermatologyPhotoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma. BMC Dermatology. 1-5.Photoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinomaCancer MedicineSurvival of patients with metastatic leiomyosarcoma. Cancer Medicine. 5:3437-3444.Survival of patients with metastatic leiomyosarcomaJournal of Medical Case ReportsTissue is the issue-sarcoidosis following ABVD chemotherapy for Hodgkin's lymphoma. Journal of Medical Case Reports. 1.Tissue is the issue-sarcoidosis following ABVD chemotherapy for Hodgkin's lymphomaMolecular Cancer TherapeuticsGenomically driven tumors and actionability across histologies. Molecular Cancer Therapeutics. 15:533-547.Genomically driven tumors and actionability across histologiesOncology (Switzerland)Comprehensive genomic profiling of clinically advanced medullary thyroid carcinoma. Oncology (Switzerland). 90:339-346.Comprehensive genomic profiling of clinically advanced medullary thyroid carcinomaOncotargetContinuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer. Oncotarget. 7:35132-35143.Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer22104361Pinnix CC, Fontanilla HP, Hayes-Jordan A, Subbiah V, Bilton SD, Chang EL, Grosshans DR, McAleer MF, Sulman EP, Woo SY, Anderson P, Green HL, Mahajan AInternational journal of radiation oncology, biology, physicsWhole abdominopelvic intensity-modulated radiation therapy for desmoplastic small round cell tumor after surgery. Int J Radiat Oncol Biol Phys. 2012 May 01; 83(1):317-26.Int J Radiat Oncol Biol Phys2011-11-19T00:00:002011Whole abdominopelvic intensity-modulated radiation therapy for desmoplastic small round cell tumor after surgery.29159766Fujii T, Colen RR, Bilen MA, Hess KR, Hajjar J, Suarez-Almazor ME, Alshawa A, Hong DS, Tsimberidou A, Janku F, Gong J, Stephen B, Subbiah V, Piha-Paul SA, Fu S, Sharma P, Mendoza T, Patel A, Thirumurthi S, Sheshadri A, Meric-Bernstam F, Naing AInvestigational new drugsIncidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Invest New Drugs. 2018 08; 36(4):638-646.Invest New Drugs2017-11-21T00:00:002017Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience.29075985Colen RR, Fujii T, Bilen MA, Kotrotsou A, Abrol S, Hess KR, Hajjar J, Suarez-Almazor ME, Alshawa A, Hong DS, Giniebra-Camejo D, Stephen B, Subbiah V, Sheshadri A, Mendoza T, Fu S, Sharma P, Meric-Bernstam F, Naing AInvestigational new drugsRadiomics to predict immunotherapy-induced pneumonitis: proof of concept. Invest New Drugs. 2018 08; 36(4):601-607.Invest New Drugs2017-10-27T00:00:002017Radiomics to predict immunotherapy-induced pneumonitis: proof of concept.Authorship 88742410Authorship 88875613Authorship 88883817Authorship 88885511Authorship 88986013D002289Disorders64653060.283287Carcinoma, Non-Small-Cell LungD057285OccupationsProcedures51311480.564622Precision MedicineD048493Chemicals & Drugs32012770.583873Proto-Oncogene Proteins B-rafD051096Chemicals & Drugs943710.804251Proto-Oncogene Proteins c-retD009369Disorders2056151140.155158NeoplasmsAuthorship 9036078Authorship 90404014Authorship 90474411Authorship 90499713Authorship 9055661Authorship 90597210Authorship 9060927Authorship 9065141Authorship 90717811Authorship 90788220Authorship 9089241Authorship 9091821Authorship 9094207Authorship 9096072Authorship 9108575Authorship 9109591Authorship 9112607Authorship 91182415Authorship 9118619Authorship 9119841Authorship 9123597Authorship 9123722Authorship 91270610Authorship 9134956Authorship 9135321Authorship 9140512Authorship 9140912Authorship 9142621Authorship 9144027Authorship 9144729Authorship 9145965Authorship 9146565Authorship 9150281Authorship 91590910Authorship 9168181Authorship 9173081Authorship 9185706Authorship 9187421Authorship 9187465Authorship 91932916Authorship 91936918Authorship 9194842Authorship 9197368Authorship 91990413Authorship 9203392Authorship 9203836Authorship 9204887Authorship 9205182Authorship 9206435Authorship 9208123Authorship 92119317Authorship 9214641Authorship 9216483Authorship 9216914Authorship 9217776Authorship 9222985Authorship 92241514Authorship 9224321Authorship 92265919Authorship 9233823Authorship 9234744Authorship 9244497Authorship 9250171Authorship 9251971Authorship 9256844Authorship 9257991Authorship 9260451Authorship 92658310Authorship 9273454Authorship 9273711Authorship 92740414Authorship 92832316Authorship 92967017Authorship 9307451Authorship 9313826Authorship 9316845Authorship 9352295Authorship 93665010Authorship 9374605Authorship 9394323Authorship 9398056Authorship 94003311Authorship 940152125126591Egas-Bejar D, Anderson PM, Agarwal R, Corrales-Medina F, Devarajan E, Huh WW, Brown RE, Subbiah VOncoscienceTheranostic Profiling for Actionable Aberrations in Advanced High Risk Osteosarcoma with Aggressive Biology Reveals High Molecular Diversity: The Human Fingerprint Hypothesis. Oncoscience. 2014 Mar 12; 1(2):167-179.Oncoscience2014-03-12T00:00:002014Theranostic Profiling for Actionable Aberrations in Advanced High Risk Osteosarcoma with Aggressive Biology Reveals High Molecular Diversity: The Human Fingerprint Hypothesis.26905772Subbiah V, Maiti AEuropean journal of internal medicineHeadache in a patient with renal cell carcinoma. Eur J Intern Med. 2016 Jul; 32:e3-4.Eur J Intern Med2016-02-20T00:00:002016Headache in a patient with renal cell carcinoma.26684814Maiti A, Brown RE, Corn PG, Murthy R, Ganeshan DM, Tsimberidou AM, Subbiah VClinical genitourinary cancerAntitumor Response to Combined Antiangiogenic and Cytotoxic Chemotherapy in Recurrent Metastatic Chromophobe Renal Cell Carcinoma: Response Signatures and Proteomic Correlates. Clin Genitourin Cancer. 2016 Apr; 14(2):e187-93.Clin Genitourin Cancer2015-11-11T00:00:002015Antitumor Response to Combined Antiangiogenic and Cytotoxic Chemotherapy in Recurrent Metastatic Chromophobe Renal Cell Carcinoma: Response Signatures and Proteomic Correlates.27078832Subbiah V, Kurzrock RJAMA oncologyUniversal Genomic Testing Needed to Win the War Against Cancer: Genomics IS the Diagnosis. JAMA Oncol. 2016 Jun 01; 2(6):719-20.JAMA Oncol2016-06-01T00:00:002016Universal Genomic Testing Needed to Win the War Against Cancer: Genomics IS the Diagnosis.26933802Liu X, Kambrick S, Fu S, Naing A, Subbiah V, Blumenschein GR, Glisson BS, Kies MS, Tsimberidou AM, Wheler JJ, Zinner RG, Hong DS, Kurzrock R, Piha-Paul SAOncotargetAdvanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. Oncotarget. 2016 Apr 26; 7(17):23227-38.Oncotarget2016-04-26T00:00:002016Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus.27009213Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Subbiah V, Rodon J, Kurzrock RMolecular cancer therapeuticsGenomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm. Mol Cancer Ther. 2016 04; 15(4):533-47.Mol Cancer Ther2016-03-23T00:00:002016Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm.27011228Subbiah V, West HLJAMA oncologyBone Complications in Patients With Cancer. JAMA Oncol. 2016 May 01; 2(5):695.JAMA Oncol2016-05-01T00:00:002016Bone Complications in Patients With Cancer.26651075Ross JS, Wang K, Khaira D, Ali SM, Fisher HA, Mian B, Nazeer T, Elvin JA, Palma N, Yelensky R, Lipson D, Miller VA, Stephens PJ, Subbiah V, Pal SKCancerComprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations. Cancer. 2016 Mar 01; 122(5):702-11.Cancer2015-12-09T00:00:002015Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations.26917690Subbiah V, Hong DS, Meric-Bernstam FProceedings of the National Academy of Sciences of the United States of AmericaClinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside report. Proc Natl Acad Sci U S A. 2016 Mar 15; 113(11):E1419-20.Proc Natl Acad Sci U S A2016-02-25T00:00:002016Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside report.27466356Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner R, Subbiah V, Fu S, Karp D, Falchook GS, Tsimberidou AM, Piha-Paul S, Anderson R, Ke D, Miller V, Yelensky R, Lee JJ, Hong D, Kurzrock RMolecular cancer therapeuticsTP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. Mol Cancer Ther. 2016 10; 15(10):2475-2485.Mol Cancer Ther2016-07-27T00:00:002016TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics.27147567Hou MM, Wang Z, Janku F, Piha-Paul S, Naing A, Hong D, Westin S, Coleman RL, Sood AK, Tsimberidou AM, Subbiah V, Wheler J, Zinner R, Lu K, Meric-Bernstam F, Fu SOncotargetContinuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. Oncotarget. 2016 Jun 07; 7(23):35132-43.Oncotarget2016-06-07T00:00:002016Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience.27207748Heilmann AM, Subbiah V, Wang K, Sun JX, Elvin JA, Chmielecki J, Sherman SI, Murthy R, Busaidy NL, Subbiah I, Yelensky R, Nangia C, Vergilio JA, Khan SA, Erlich RL, Lipson D, Ross JS, Miller VA, Shah MH, Ali SM, Stephens PJOncologyComprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma. Oncology. 2016; 90(6):339-46.Oncology2016-05-21T00:00:002016Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.27576731Lamhamedi-Cherradi SE, Menegaz BA, Ramamoorthy V, Vishwamitra D, Wang Y, Maywald RL, Buford AS, Fokt I, Skora S, Wang J, Naing A, Lazar AJ, Rohren EM, Daw NC, Subbiah V, Benjamin RS, Ratan R, Priebe W, Mikos AG, Amin HM, Ludwig JAJournal of the National Cancer InstituteIGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma. J Natl Cancer Inst. 2016 12; 108(12).J Natl Cancer Inst2016-08-30T00:00:002016IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma.27649551Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, Basu S, Curran MA, Cabanillas ME, Subbiah V, Fu S, Tsimberidou AM, Karp D, Gomez DR, Diab A, Komaki R, Heymach JV, Sharma P, Naing A, Hong DSClinical cancer research : an official journal of the American Association for Cancer ResearchIpilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. Clin Cancer Res. 2017 Mar 15; 23(6):1388-1396.Clin Cancer Res2016-09-20T00:00:002016Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells.27197177Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner R, Subbiah V, Fu S, Karp D, Falchook GS, Tsimberidou AM, Piha-Paul S, Anderson R, Ke D, Miller V, Yelensky R, Lee JJ, Hong DS, Kurzrock RCancer researchCancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. Cancer Res. 2016 07 01; 76(13):3690-701.Cancer Res2016-05-18T00:00:002016Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study.27412379George GC, Iwuanyanwu EC, Anderson KO, Yusuf A, Zinner RG, Piha-Paul SA, Tsimberidou AM, Naing A, Fu S, Janku F, Subbiah V, Cleeland CS, Mendoza TR, Hong DSCancerSleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials. Cancer. 2016 Nov 15; 122(21):3401-3409.Cancer2016-07-14T00:00:002016Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials.27416009Subbiah V, West HJJAMA oncologyJaundice (Hyperbilirubinemia) in Cancer. JAMA Oncol. 2016 Aug 01; 2(8):1103.JAMA Oncol2016-08-01T00:00:002016Jaundice (Hyperbilirubinemia) in Cancer.27486883Livingston JA, Hess KR, Naing A, Hong DS, Patel S, Benjamin RS, Ludwig JA, Conley A, Herzog CE, Anderson P, Meric-Bernstam F, Kurzrock R, Subbiah VOncotargetValidation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. Oncotarget. 2016 Sep 27; 7(39):64421-64430.Oncotarget2016-09-27T00:00:002016Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials.27589687Park H, Garrido-Laguna I, Naing A, Fu S, Falchook GS, Piha-Paul SA, Wheler JJ, Hong DS, Tsimberidou AM, Subbiah V, Zinner RG, Kaseb AO, Patel S, Fanale MA, Velez-Bravo VM, Meric-Bernstam F, Kurzrock R, Janku FOncotargetPhase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget. 2016 Oct 11; 7(41):67521-67531.Oncotarget2016-10-11T00:00:002016Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy.27748430Subbiah V, Hess KR, Khawaja MR, Wagner MJ, Tang C, Naing A, Fu S, Janku F, Piha-Paul S, Tsimberidou AM, Herzog CE, Ludwig JA, Patel S, Ravi V, Benjamin RS, Meric-Bernstam F, Hong DSScientific reportsEvaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. Sci Rep. 2016 10 17; 6:35448.Sci Rep2016-10-17T00:00:002016Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies.27882721Wang Z, Shi N, Naing A, Janku F, Subbiah V, Araujo DM, Patel SR, Ludwig JA, Ramondetta LM, Levenback CF, Ramirez PT, Piha-Paul SA, Hong D, Karp DD, Tsimberidou AM, Meric-Bernstam F, Fu SCancer medicineSurvival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. Cancer Med. 2016 12; 5(12):3437-3444.Cancer Med2016-11-23T00:00:002016Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience.27893038Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Ibrahim NK, Murray JL, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder SLJAMA oncologyTargeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol. 2017 Apr 01; 3(4):509-515.JAMA Oncol2017-04-01T00:00:002017Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab.27729313Hong DS, Morris VK, El Osta B, Sorokin AV, Janku F, Fu S, Overman MJ, Piha-Paul S, Subbiah V, Kee B, Tsimberidou AM, Fogelman D, Bellido J, Shureiqi I, Huang H, Atkins J, Tarcic G, Sommer N, Lanman R, Meric-Bernstam F, Kopetz SCancer discoveryPhase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Cancer Discov. 2016 12; 6(12):1352-1365.Cancer Discov2016-10-11T00:00:002016Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.27802448Kinahan H, Maiti A, Hess K, Dempsey J, Beatty L, Baldwin S, Hong DS, Naing A, Fu S, Tsimberidou AM, Piha-Paul S, Janku F, Karp D, Reddy S, Yennu S, Epner D, Bruera E, Meric-Bernstam F, Falchook G, Subbiah VOncologyPost-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit. Oncology. 2017; 92(1):14-20.Oncology2016-11-02T00:00:002016Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit.27683183Kato S, Subbiah V, Marchlik E, Elkin SK, Carter JL, Kurzrock RClinical cancer research : an official journal of the American Association for Cancer ResearchRET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients. Clin Cancer Res. 2017 04 15; 23(8):1988-1997.Clin Cancer Res2016-09-28T00:00:002016RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients.27764830Subbiah V, Holmes O, Gowen K, Spritz D, Amini B, Wang WL, Schrock AB, Meric-Bernstam F, Zinner R, Piha-Paul S, Zarzour M, Elvin JA, Erlich RL, Stockman DL, Vergilio JA, Suh JH, Stephens PJ, Miller V, Ross JS, Ali SMOncologyActivity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion. Oncology. 2016; 91(6):348-353.Oncology2016-10-21T00:00:002016Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion.28096270Fujii T, Barzi A, Sartore-Bianchi A, Cassingena A, Siravegna G, Karp DD, Piha-Paul SA, Subbiah V, Tsimberidou AM, Huang HJ, Veronese S, Di Nicolantonio F, Pingle S, Vibat CRT, Hancock S, Berz D, Melnikova VO, Erlander MG, Luthra R, Kopetz ES, Meric-Bernstam F, Siena S, Lenz HJ, Bardelli A, Janku FClinical cancer research : an official journal of the American Association for Cancer ResearchMutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. Clin Cancer Res. 2017 Jul 15; 23(14):3657-3666.Clin Cancer Res2017-01-17T00:00:002017Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers.28212290Subbiah V, Chuang HH, Gambhire D, Kairemo KDiagnostics (Basel, Switzerland)Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives. Diagnostics (Basel). 2017 Feb 15; 7(1).Diagnostics (Basel)2017-02-15T00:00:002017Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives.28375169Kairemo K, Ravizzini GC, Macapinlac HA, Subbiah VDiagnostics (Basel, Switzerland)An Assessment of Early Response to Targeted Therapy via Molecular Imaging: A Pilot Study of 3'-deoxy-3'[(18)F]-Fluorothymidine Positron Emission Tomography 18F-FLT PET/CT in Prostate Adenocarcinoma. Diagnostics (Basel). 2017 Apr 04; 7(2).Diagnostics (Basel)2017-04-04T00:00:002017An Assessment of Early Response to Targeted Therapy via Molecular Imaging: A Pilot Study of 3'-deoxy-3'[(18)F]-Fluorothymidine Positron Emission Tomography 18F-FLT PET/CT in Prostate Adenocarcinoma.28377484Subbiah V, Meyer C, Zinner R, Meric-Bernstam F, Zahurak ML, O'Connor A, Roszik J, Shaw K, Ludwig JA, Kurzrock R, Azad NAClinical cancer research : an official journal of the American Association for Cancer ResearchPhase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma. Clin Cancer Res. 2017 08 01; 23(15):4027-4034.Clin Cancer Res2017-04-04T00:00:002017Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma.28428884Reilley MJ, Bailey A, Subbiah V, Janku F, Naing A, Falchook G, Karp D, Piha-Paul S, Tsimberidou A, Fu S, Lim J, Bean S, Bass A, Montez S, Vence L, Sharma P, Allison J, Meric-Bernstam F, Hong DSJournal for immunotherapy of cancerPhase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. J Immunother Cancer. 2017; 5:35.J Immunother Cancer2017-04-18T00:00:002017Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies.28430579Wang Z, Piha-Paul S, Janku F, Subbiah V, Shi N, Gong J, Wathoo C, Shaw K, Hess K, Broaddus R, Naing A, Hong D, Tsimberidou AM, Karp D, Yao J, Meric-Bernstam F, Fu SOncotargetAntiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. Oncotarget. 2017 May 16; 8(20):33796-33806.Oncotarget2017-05-16T00:00:002017Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer.28441383Shroff RT, Yarchoan M, O'Connor A, Gallagher D, Zahurak ML, Rosner G, Ohaji C, Sartorius-Mergenthaler S, Subbiah V, Zinner R, Azad NSBritish journal of cancerThe oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma. Br J Cancer. 2017 05 23; 116(11):1402-1407.Br J Cancer2017-04-25T00:00:002017The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.28550030Subbiah V, Kurzrock RThe oncologistDebunking the Delusion That Precision Oncology Is an Illusion. Oncologist. 2017 08; 22(8):881-882.Oncologist2017-05-26T00:00:002017Debunking the Delusion That Precision Oncology Is an Illusion.28318386Subbiah V, Roszik JCell cycle (Georgetown, Tex.)Towards precision oncology in RET-aberrant cancers. Cell Cycle. 2017 05 03; 16(9):813-814.Cell Cycle2017-03-20T00:00:002017Towards precision oncology in RET-aberrant cancers.28422758Subbiah V, Khawaja MR, Hong DS, Amini B, Yungfang J, Liu H, Johnson A, Schrock AB, Ali SM, Sun JX, Fabrizio D, Piha-Paul S, Fu S, Tsimberidou AM, Naing A, Janku F, Karp DD, Overman M, Eng C, Kopetz S, Meric-Bernstam F, Falchook GSJCI insightFirst-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. JCI Insight. 2017 Apr 20; 2(8).JCI Insight2017-04-20T00:00:002017First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients.28424409Groisberg R, Hong DS, Holla V, Janku F, Piha-Paul S, Ravi V, Benjamin R, Kumar Patel S, Somaiah N, Conley A, Ali SM, Schrock AB, Ross JS, Stephens PJ, Miller VA, Sen S, Herzog C, Meric-Bernstam F, Subbiah VOncotargetClinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Oncotarget. 2017 Jun 13; 8(24):39254-39267.Oncotarget2017-06-13T00:00:002017Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.28536309Janku F, Zhang S, Waters J, Liu L, Huang HJ, Subbiah V, Hong DS, Karp DD, Fu S, Cai X, Ramzanali NM, Madwani K, Cabrilo G, Andrews DL, Zhao Y, Javle M, Kopetz ES, Luthra R, Kim HJ, Gnerre S, Satya RV, Chuang HY, Kruglyak KM, Toung J, Zhao C, Shen R, Heymach JV, Meric-Bernstam F, Mills GB, Fan JB, Salathia NSClinical cancer research : an official journal of the American Association for Cancer ResearchDevelopment and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. Clin Cancer Res. 2017 Sep 15; 23(18):5648-5656.Clin Cancer Res2017-05-23T00:00:002017Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer.28729355Kehl KL, Fullmer CP, Fu S, George GC, Hess KR, Janku F, Karp DD, Kato S, Kizer CK, Kurzrock R, Naing A, Pant S, Piha-Paul SA, Subbiah V, Tsimberidou AM, Hong DSClinical cancer research : an official journal of the American Association for Cancer ResearchInsurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act. Clin Cancer Res. 2017 Aug 01; 23(15):4155-4162.Clin Cancer Res2017-07-20T00:00:002017Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act.29072975Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B, Wang D, Rangwala F, Keam BJournal of clinical oncology : official journal of the American Society of Clinical OncologyDabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. J Clin Oncol. 2018 01 01; 36(1):7-13.J Clin Oncol2017-10-26T00:00:002017Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.28781987Subbiah IM, Tsimberidou A, Subbiah V, Janku F, Roy-Chowdhuri S, Hong DSOncoscienceNext generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape. Oncoscience. 2017 May; 4(5-6):47-56.Oncoscience2017-06-23T00:00:002017Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape.29051321M?hrmann L, Huang HJ, Hong DS, Tsimberidou AM, Fu S, Piha-Paul SA, Subbiah V, Karp DD, Naing A, Krug A, Enderle D, Priewasser T, Noerholm M, Eitan E, Coticchia C, Stoll G, Jordan LM, Eng C, Kopetz ES, Skog J, Meric-Bernstam F, Janku FClinical cancer research : an official journal of the American Association for Cancer ResearchLiquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. Clin Cancer Res. 2018 01 01; 24(1):181-188.Clin Cancer Res2017-10-19T00:00:002017Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers.29117359Sen S, Meric-Bernstam F, Hong DS, Hess KR, Subbiah VJournal of the National Cancer InstituteCo-occurring Genomic Alterations and Association With Progression-Free Survival in BRAFV600-Mutated Nonmelanoma Tumors. J Natl Cancer Inst. 2017 10 01; 109(10).J Natl Cancer Inst2017-10-01T00:00:002017Co-occurring Genomic Alterations and Association With Progression-Free Survival in BRAFV600-Mutated Nonmelanoma Tumors.29119847Strati P, Tang G, Duose DY, Mallampati S, Luthra R, Patel KP, Hussaini M, Mirza AS, Komrokji RS, Oh S, Mascarenhas J, Najfeld V, Subbiah V, Kantarjian H, Garcia-Manero G, Verstovsek S, Daver NLeukemia & lymphomaMyeloid/lymphoid neoplasms with FGFR1 rearrangement. Leuk Lymphoma. 2018 07; 59(7):1672-1676.Leuk Lymphoma2017-11-09T00:00:002017Myeloid/lymphoid neoplasms with FGFR1 rearrangement.29188284Diamond EL, Subbiah V, Lockhart AC, Blay JY, Puzanov I, Chau I, Raje NS, Wolf J, Erinjeri JP, Torrisi J, Lacouture M, Elez E, Mart?nez-Valle F, Durham B, Arcila ME, Ulaner G, Abdel-Wahab O, Pitcher B, Makrutzki M, Riehl T, Baselga J, Hyman DMJAMA oncologyVemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study. JAMA Oncol. 2018 Mar 01; 4(3):384-388.JAMA Oncol2018-03-01T00:00:002018Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.29189398Ghosh P, Chandler AG, Hobbs BP, Sun J, Rong J, Hong D, Subbiah V, Janku F, Naing A, Hwu WJ, Ng CSJournal of computer assisted tomographyQuantification of the Effect of Shuttling on Computed Tomography Perfusion Parameters by Investigation of Aortic Inputs on Different Table Positions From Shuttle-Mode Scans of Lung and Liver Tumors. J Comput Assist Tomogr. 2018 May/Jun; 42(3):357-364.J Comput Assist Tomogr2018-05-01T00:00:002018Quantification of the Effect of Shuttling on Computed Tomography Perfusion Parameters by Investigation of Aortic Inputs on Different Table Positions From Shuttle-Mode Scans of Lung and Liver Tumors.29237802Sakamuri D, Glitza IC, Betancourt Cuellar SL, Subbiah V, Fu S, Tsimberidou AM, Wheler JJ, Hong DS, Naing A, Falchook GS, Fanale MA, Cabanillas ME, Janku FMolecular cancer therapeuticsPhase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers. Mol Cancer Ther. 2018 03; 17(3):671-676.Mol Cancer Ther2017-12-13T00:00:002017Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers.29243227Subbiah V, Rodon J, Yap TAInternational journal of cancerPrecision oncology: East meets West. Int J Cancer. 2018 05 01; 142(9):1734-1737.Int J Cancer2018-01-04T00:00:002018Precision oncology: East meets West.29047029Kato S, Jardim DL, Johnson FM, Subbiah V, Piha-Paul S, Tsimberidou AM, Falchook GS, Karp D, Zinner R, Wheler J, Janku F, Fu S, Lim J, Bean S, Nguyen L, Urban S, Browne E, Meric-Bernstam F, Hong DSInvestigational new drugsPhase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer. Invest New Drugs. 2018 06; 36(3):416-423.Invest New Drugs2017-10-19T00:00:002017Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer.29162825Dembla V, Groisberg R, Hess K, Fu S, Wheler J, Hong DS, Janku F, Zinner R, Piha-Paul SA, Ravi V, Benjamin RS, Patel S, Somaiah N, Herzog CE, Karp DD, Roszik J, Meric-Bernstam F, Subbiah VScientific reportsOutcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. Sci Rep. 2017 11 21; 7(1):15963.Sci Rep2017-11-21T00:00:002017Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.29167828Groisberg R, Subbiah VTranslational gastroenterology and hepatologyThe big, the bad, and the exon 11: adjuvant imatinib for all gastro-intestinal stromal tumors or just the ugly? Transl Gastroenterol Hepatol. 2017; 2:81.Transl Gastroenterol Hepatol2017-10-13T00:00:002017The big, the bad, and the exon 11: adjuvant imatinib for all gastro-intestinal stromal tumors or just the ugly?28687573Kato S, Subbiah V, Kurzrock RJournal of the National Comprehensive Cancer Network : JNCCNCounterpoint: Successes in the Pursuit of Precision Medicine: Biomarkers Take Credit. J Natl Compr Canc Netw. 2017 07; 15(7):863-866.J Natl Compr Canc Netw2017-07-01T00:00:002017Counterpoint: Successes in the Pursuit of Precision Medicine: Biomarkers Take Credit.29030354Subbiah V, Grilley-Olson JE, Combest AJ, Sharma N, Tran RH, Bobe I, Osada A, Takahashi K, Balkissoon J, Camp A, Masada A, Reitsma DJ, Bazhenova LAClinical cancer research : an official journal of the American Association for Cancer ResearchPhase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients with Advanced Solid Tumors. Clin Cancer Res. 2018 01 01; 24(1):43-51.Clin Cancer Res2017-10-13T00:00:002017Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients with Advanced Solid Tumors.29030741Groisberg R, Roszik J, Conley A, Patel SR, Subbiah VCurrent oncology reportsThe Role of Next-Generation Sequencing in Sarcomas: Evolution From Light Microscope to Molecular Microscope. Curr Oncol Rep. 2017 Oct 13; 19(12):78.Curr Oncol Rep2017-10-13T00:00:002017The Role of Next-Generation Sequencing in Sarcomas: Evolution From Light Microscope to Molecular Microscope.29254498Groisberg R, Hong DS, Behrang A, Hess K, Janku F, Piha-Paul S, Naing A, Fu S, Benjamin R, Patel S, Somaiah N, Conley A, Meric-Bernstam F, Subbiah VJournal for immunotherapy of cancerCharacteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. J Immunother Cancer. 2017 12 19; 5(1):100.J Immunother Cancer2017-12-19T00:00:002017Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials.29315294Shroff RT, Yarchoan M, O'Connor A, Gallagher D, Zahurak ML, Rosner G, Ohaji C, Sartorius-Mergenthaler S, Parkinson R, Subbiah V, Zinner R, Azad NSBritish journal of cancerThe oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma. Br J Cancer. 2018 01; 118(2):e2.Br J Cancer2018-01-09T00:00:002018The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.29695765Sen S, Kato S, Agarwal R, Piha-Paul S, Hess K, Karp D, Janku F, Fu S, Naing A, Pant S, Falchook G, Tang C, Wu X, Ye Y, Tsimberidou A, Subbiah V, Kurzrock R, Byers L, Westin S, Lim J, Bean S, Bass A, Nguyen L, Meric-Bernstam F, Hong DBritish journal of cancerPhase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. Br J Cancer. 2018 05; 118(11):1419-1424.Br J Cancer2018-04-26T00:00:002018Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers.29458960Subbiah V, Kurzrock RTrends in cancerChallenging Standard-of-Care Paradigms in the Precision Oncology Era. Trends Cancer. 2018 02; 4(2):101-109.Trends Cancer2018-01-12T00:00:002018Challenging Standard-of-Care Paradigms in the Precision Oncology Era.29462132Sen S, Hess K, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Subbiah IM, Liu H, Khanji R, Huang L, Moorthy S, Karp DD, Tsimberidou A, Meric-Bernstam F, Subbiah VBritish journal of cancerDevelopment of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials. Br J Cancer. 2018 03 20; 118(6):763-769.Br J Cancer2018-02-20T00:00:002018Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials.29668571Parseghian CM, Patnana M, Bhosale P, Hess KR, Shih YT, Kim B, Kopetz S, Overman MJ, Varadhachary GR, Javle M, Naing A, Piha-Paul S, Hong D, Le H, Subbiah V, Pant SJournal of immunotherapy (Hagerstown, Md. : 1997)Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. J Immunother. 2018 Jul/Aug; 41(6):284-291.J Immunother2018-07-01T00:00:002018Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy.29748008Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Tsimberidou AM, Pant S, Karp D, Liu S, Sun M, Heymach J, Simon G, Meric-Bernstam F, Subbiah VLung cancer (Amsterdam, Netherlands)Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. Lung Cancer. 2018 06; 120:137-141.Lung Cancer2018-04-11T00:00:002018Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials.29582189El Beaino M, Roszik J, Livingston JA, Wang WL, Lazar AJ, Amini B, Subbiah V, Lewis V, Conley APCurrent oncology reportsMesenchymal Chondrosarcoma: a Review with Emphasis on its Fusion-Driven Biology. Curr Oncol Rep. 2018 03 26; 20(5):37.Curr Oncol Rep2018-03-26T00:00:002018Mesenchymal Chondrosarcoma: a Review with Emphasis on its Fusion-Driven Biology.29654067Groisberg R, Hong DS, Roszik J, Janku F, Tsimberidou AM, Javle M, Meric-Bernstam F, Subbiah VMolecular cancer therapeuticsClinical Next-Generation Sequencing for Precision Oncology in Rare Cancers. Mol Cancer Ther. 2018 07; 17(7):1595-1601.Mol Cancer Ther2018-04-13T00:00:002018Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers.29657135Subbiah V, Gainor JF, Rahal R, Brubaker JD, Kim JL, Maynard M, Hu W, Cao Q, Sheets MP, Wilson D, Wilson KJ, DiPietro L, Fleming P, Palmer M, Hu MI, Wirth L, Brose MS, Ou SI, Taylor M, Garralda E, Miller S, Wolf B, Lengauer C, Guzi T, Evans EKCancer discoveryPrecision Targeted Therapy with BLU-667 for RET-Driven Cancers. Cancer Discov. 2018 07; 8(7):836-849.Cancer Discov2018-04-15T00:00:002018Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.29152071Goldstein JB, Tang C, Hess KR, Hong D, Subbiah V, Janku F, Fu S, Karp DD, Naing A, Tsimberidou AM, Wheler J, Zinner R, Javle M, Varadhachary GR, Wolff RA, Fogelman DR, Meric-Bernstam F, Piha-Paul SAOncotargetOutcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. Oncotarget. 2017 Oct 20; 8(50):87163-87173.Oncotarget2017-08-03T00:00:002017Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience.29212731Menegaz BA, Cuglievan B, Benson J, Camacho P, Lamhamedi-Cherradi SE, Leung CH, Warneke CL, Huh W, Subbiah V, Benjamin RS, Patel S, Daw N, Hayes-Jordan A, Ludwig JAThe oncologistClinical Activity of Pazopanib in Patients with Advanced Desmoplastic Small Round Cell Tumor. Oncologist. 2018 03; 23(3):360-366.Oncologist2017-12-06T00:00:002017Clinical Activity of Pazopanib in Patients with Advanced Desmoplastic Small Round Cell Tumor.29413466Ileana-Dumbrava E, Subbiah VThe Lancet. OncologyAutoimmune hypophysitis. Lancet Oncol. 2018 02; 19(2):e123.Lancet Oncol2018-02-01T00:00:002018Autoimmune hypophysitis.29937043Roszik J, Subbiah VTrends in cancerMining Public Databases for Precision Oncology. Trends Cancer. 2018 07; 4(7):463-465.Trends Cancer2018-05-22T00:00:002018Mining Public Databases for Precision Oncology.30148248Kato S, Ross JS, Gay L, Dayyani F, Roszik J, Subbiah V, Kurzrock RJCO precision oncologyAnalysis of MDM2 Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies. JCO Precis Oncol. 2018; 2018.JCO Precis Oncol2018-07-13T00:00:002018Analysis of MDM2 Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies.30279957Wang Y, Wang Z, Piha-Paul S, Janku F, Subbiah V, Shi N, Hess K, Broaddus R, Shan B, Naing A, Hong D, Tsimberidou AM, Karp D, Lu C, Papadimitrakopoulou V, Heymach J, Meric-Bernstam F, Fu SOncotargetOutcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer. Oncotarget. 2018 Sep 07; 9(70):33258-33270.Oncotarget2018-09-07T00:00:002018Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer.29989021Subbiah IM, Tang C, Rao A, Falchook GS, Subbiah V, Tsimberidou AM, Karp D, Kurzrock R, Hong DSOncotargetOlder adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors. Oncotarget. 2018 Jun 22; 9(48):28842-28848.Oncotarget2018-06-22T00:00:002018Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors.29801033Dumbrava EI, Ivan D, Subbiah VJAMA oncologyHypopigmented Skin Lesions After Immunotherapy. JAMA Oncol. 2018 08 01; 4(8):1118-1119.JAMA Oncol2018-08-01T00:00:002018Hypopigmented Skin Lesions After Immunotherapy.30182147Fountzilas E, Krishnan E, Janku F, Fu S, Karp DD, Naing A, Subbiah V, Hong DS, Piha-Paul SA, Vining DJ, Tsimberidou AMCancer chemotherapy and pharmacologyA phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement. Cancer Chemother Pharmacol. 2018 11; 82(5):877-885.Cancer Chemother Pharmacol2018-09-04T00:00:002018A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement.30237864Dembla V, Somaiah N, Barata P, Hess K, Fu S, Janku F, Karp DD, Naing A, Piha-Paul SA, Subbiah V, Tsimberidou AM, Shaw K, Meric-Bernstam F, Hong DSOncotargetPrevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic. Oncotarget. 2018 Sep 04; 9(69):33232-33243.Oncotarget2018-09-04T00:00:002018Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic.30320296Johnson A, Khotskaya YB, Brusco L, Zeng J, Holla V, Bailey AM, Litzenburger BC, Sanchez N, Shufean MA, Piha-Paul S, Subbiah V, Hong D, Routbort M, Broaddus R, Mills Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam FJCO precision oncologyClinical Use of Precision Oncology Decision Support. JCO Precis Oncol. 2017; 2017.JCO Precis Oncol2017-09-13T00:00:002017Clinical Use of Precision Oncology Decision Support.29871905Subbiah V, Lamhamedi-Cherradi SE, Cuglievan B, Menegaz BA, Camacho P, Huh W, Ramamoorthy V, Anderson PM, Pollock RE, Lev DC, Qiao W, McAleer MF, Benjamin RS, Patel S, Herzog CE, Daw NC, Feig BW, Lazar AJ, Hayes-Jordan A, Ludwig JAClinical cancer research : an official journal of the American Association for Cancer ResearchMultimodality Treatment of Desmoplastic Small Round Cell Tumor: Chemotherapy and Complete Cytoreductive Surgery Improve Patient Survival. Clin Cancer Res. 2018 10 01; 24(19):4865-4873.Clin Cancer Res2018-06-05T00:00:002018Multimodality Treatment of Desmoplastic Small Round Cell Tumor: Chemotherapy and Complete Cytoreductive Surgery Improve Patient Survival.30018119Subbiah V, Murthy R, Hong DS, Prins RM, Hosing C, Hendricks K, Kolli D, Noffsinger L, Brown R, McGuire M, Fu S, Piha-Paul S, Naing A, Conley AP, Benjamin RS, Kaur I, Bosch MLClinical cancer research : an official journal of the American Association for Cancer ResearchCytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers. Clin Cancer Res. 2018 08 15; 24(16):3845-3856.Clin Cancer Res2018-07-17T00:00:002018Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers.30021048Arudra K, Patel R, Tetzlaff MT, Hymes S, Subbiah V, Meric-Bernstam F, Torres-Cabala C, Aung PP, Nagarajan P, Diab A, Prieto VG, Nelson K, Curry JLJournal of cutaneous pathologyCalcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor. J Cutan Pathol. 2018 Oct; 45(10):786-790.J Cutan Pathol2018-08-03T00:00:002018Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor.30352943Subbiah V, Kurzrock RThe oncologistThe Marriage Between Genomics and Immunotherapy: Mismatch Meets Its Match. Oncologist. 2019 01; 24(1):1-3.Oncologist2018-10-23T00:00:002018The Marriage Between Genomics and Immunotherapy: Mismatch Meets Its Match.30733229Subbiah V, Anderson PM, Kairemo K, Hess K, Huh WW, Ravi V, Daw NC, Somaiah N, Ludwig JA, Benjamin RS, Chawla S, Hong DS, Meric-Bernstam F, Ravizzini G, Kleinerman E, Macapinlac H, Rohren EClinical cancer research : an official journal of the American Association for Cancer ResearchAlpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial. Clin Cancer Res. 2019 07 01; 25(13):3802-3810.Clin Cancer Res2019-02-07T00:00:002019Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial.30652536Gianni M, Qin Y, Wenes G, Bandstra B, Conley AP, Subbiah V, Leibowitz-Amit R, Ekmekcioglu S, Grimm EA, Roszik JJCO clinical cancer informaticsHigh-Throughput Architecture for Discovering Combination Cancer Therapeutics. JCO Clin Cancer Inform. 2018 12; 2:1-12.JCO Clin Cancer Inform2018-12-01T00:00:002018High-Throughput Architecture for Discovering Combination Cancer Therapeutics.30652565George GC, Buford A, Hess K, Piha-Paul SA, Zinner R, Subbiah V, Hinojosa C, Cleeland CS, Meric-Bernstam F, Bernstam EV, Hong DSJCO clinical cancer informaticsCancer-Related Internet Use and Online Social Networking Among Patients in an Early-Phase Clinical Trials Clinic at a Comprehensive Cancer Center. JCO Clin Cancer Inform. 2018 12; 2:1-14.JCO Clin Cancer Inform2018-12-01T00:00:002018Cancer-Related Internet Use and Online Social Networking Among Patients in an Early-Phase Clinical Trials Clinic at a Comprehensive Cancer Center.30383888Bhatty M, Kato S, Piha-Paul SA, Naing A, Subbiah V, Huang HJ, Karp DD, Tsimberidou AM, Zinner RG, Hwu WJ, Javle M, Patel SP, Hu MI, Varadhachary GR, Conley AP, Ramzanali NM, Holley VR, Kurzrock R, Meric-Bernstam F, Kwang Chae Y, Kim KB, Falchook GS, Janku FCancerPhase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies. Cancer. 2019 02 01; 125(3):463-472.Cancer2018-11-01T00:00:002018Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies.30695675Menta AK, Subbiah IM, Subbiah VDiscovery medicineBringing wearable devices into oncology practice: fitting smart technology in the clinic. Discov Med. 2018 12; 26(145):261-270.Discov Med2018-12-01T00:00:002018Bringing wearable devices into oncology practice: fitting smart technology in the clinic.Authorship 9408694Authorship 940998530869638George GC, Iwuanyanwu EC, Buford AS, Piha-Paul SA, Subbiah V, Fu S, Karp DD, Pant S, Hinojosa CO, Hess KR, Cleeland CS, Bernstam EV, Meric-Bernstam F, Hong DSJournal of medical Internet researchCancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study. J Med Internet Res. 2019 03 14; 21(3):e10348.J Med Internet Res2019-03-14T00:00:002019Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study.30792639Grinshpun A, Zarbiv Y, Roszik J, Subbiah V, Hubert ACase reports in oncologyBeyond KRAS: Practical Molecular Targets in Pancreatic Adenocarcinoma. Case Rep Oncol. 2019 Jan-Apr; 12(1):7-13.Case Rep Oncol2019-01-04T00:00:002019Beyond KRAS: Practical Molecular Targets in Pancreatic Adenocarcinoma.Authorship 943432424984810Allareddy V, Elangovan S, Fletcher SL, Subbiah V, Rampa S, Nalliah R, Lee MK, Allareddy VOral surgery, oral medicine, oral pathology and oral radiologyIncidence and impact of adverse effects of medical care on complications in patients who underwent excision of cervical lymph nodes. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014 Sep; 118(3):271-7.Oral Surg Oral Med Oral Pathol Oral Radiol2014-05-14T00:00:002014Incidence and impact of adverse effects of medical care on complications in patients who underwent excision of cervical lymph nodes.Authorship 944181330351999Kaley T, Touat M, Subbiah V, Hollebecque A, Rodon J, Lockhart AC, Keedy V, Bielle F, Hofheinz RD, Joly F, Blay JY, Chau I, Puzanov I, Raje NS, Wolf J, DeAngelis LM, Makrutzki M, Riehl T, Pitcher B, Baselga J, Hyman DMJournal of clinical oncology : official journal of the American Society of Clinical OncologyBRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study. J Clin Oncol. 2018 12 10; 36(35):3477-3484.J Clin Oncol2018-10-23T00:00:002018BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study.Authorship 944999730962954Kairemo K, Rohren EM, Anderson PM, Ravizzini G, Rao A, Macapinlac HA, Subbiah VESMO openDevelopment of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST. ESMO Open. 2019; 4(1):e000439.ESMO Open2019-02-28T00:00:002019Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST.Authorship 945588331015231Kairemo K, Wang WL, Subbiah VBMJ case reportsComprehensive molecular imaging of malignant transformation of giant cell tumour of bone reveals diverse disease biology. BMJ Case Rep. 2019 Apr 23; 12(4).BMJ Case Rep2019-04-23T00:00:002019Comprehensive molecular imaging of malignant transformation of giant cell tumour of bone reveals diverse disease biology.Authorship 946528231061188Kairemo K, Subbiah VBMJ case reportsMolecular imaging of metastatic atrial angiosarcoma with positron emission tomography (PET) tracer 3'-deoxy-3'[(18)F]-fluorothymidine, [(18)F]-FLT imaging and early response evaluation. BMJ Case Rep. 2019 May 06; 12(5).BMJ Case Rep2019-05-06T00:00:002019Molecular imaging of metastatic atrial angiosarcoma with positron emission tomography (PET) tracer 3'-deoxy-3'[(18)F]-fluorothymidine, [(18)F]-FLT imaging and early response evaluation.21936711Subbiah V, Angelo LS, Kurzrock RExpert opinion on investigational drugsInsulin-like growth factor 1 receptor (IGF-1R) inhibitor: another arrow in the quiver - Will it hit the moving target? Expert Opin Investig Drugs. 2011 Nov; 20(11):1471-7.Expert Opin Investig Drugs2011-09-21T00:00:002011Insulin-like growth factor 1 receptor (IGF-1R) inhibitor: another arrow in the quiver - Will it hit the moving target?23800680Jiang Y, Janku F, Subbiah V, Angelo LS, Naing A, Anderson PM, Herzog CE, Fu S, Benjamin RS, Kurzrock ROncotargetGermline PTPRD mutations in Ewing sarcoma: biologic and clinical implications. Oncotarget. 2013 Jun; 4(6):884-9.Oncotarget2013-06-01T00:00:002013Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications.Authorship 9471211331096717Conley AP, Wang WL, Livingston JA, Ravi V, Tsai JW, Ali A, Ingram DR, Lowery CD, Roland CL, Somaiah N, Hwu P, Yee C, Subbiah V, Futreal A, Lazar AJ, Patel S, Roszik JCancersMAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. Cancers (Basel). 2019 May 15; 11(5).Cancers (Basel)2019-05-15T00:00:002019MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma.Authorship 948979531186313Kurzrock R, Ball DW, Zahurak ML, Nelkin BD, Subbiah V, Ahmed S, O'Connor A, Karunsena E, Parkinson RM, Bishop JA, Ha Y, Sharma R, Gocke CD, Zinner R, Rudek MA, Sherman SI, Azad NSClinical cancer research : an official journal of the American Association for Cancer ResearchA Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers. Clin Cancer Res. 2019 09 15; 25(18):5475-5484.Clin Cancer Res2019-06-11T00:00:002019A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers.Authorship 950513531233590Doan HQ, Hu MI, Goldstein J, Piha-Paul SA, Subbiah V, Patel ABCutisVandetanib photoinduced cutaneous toxicities. Cutis. 2019 May; 103(5):E24-E29.Cutis2019-05-01T00:00:002019Vandetanib photoinduced cutaneous toxicities.Authorship 9517611131300450Rich TA, Reckamp KL, Chae YK, Doebele RC, Iams WT, Oh M, Raymond VM, Lanman RB, Riess JW, Stinchcombe TE, Subbiah V, Trevarthen DR, Fairclough S, Yen J, Gautschi OClinical cancer research : an official journal of the American Association for Cancer ResearchAnalysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations. Clin Cancer Res. 2019 10 01; 25(19):5832-5842.Clin Cancer Res2019-07-12T00:00:002019Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations.Authorship 952176131319384Subbiah V, Sircar KJournal of the National Comprehensive Cancer Network : JNCCNPersonalizing Precision Oncology: From Light Microscope to Molecular Microscope. J Natl Compr Canc Netw. 2019 07 01; 17(7):886-888.J Natl Compr Canc Netw2019-07-01T00:00:002019Personalizing Precision Oncology: From Light Microscope to Molecular Microscope.Authorship 952502331337656Adashek JJ, Subbiah IM, Subbiah VThe oncologistArtificial Intelligence Systems Assisting Oncologists? Resist and Desist or Enlist and Coexist. Oncologist. 2019 10; 24(10):1291-1293.Oncologist2019-07-23T00:00:002019Artificial Intelligence Systems Assisting Oncologists? Resist and Desist or Enlist and Coexist.Authorship 9543671731445783Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Tsimberidou AM, Pant S, Karp D, Liu S, Sun M, Heymach J, Simon G, Meric-Bernstam F, Subbiah VLung cancer (Amsterdam, Netherlands)Corrigendum to "Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials" [Lung Cancer 120 (June) (2018) 137-141]. Lung Cancer. 2019 Oct; 136:158.Lung Cancer2019-08-21T00:00:002019Corrigendum to "Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials" [Lung Cancer 120 (June) (2018) 137-141].Authorship 954857931480474Roszik J, Khan A, Conley AP, Livingston JA, Groisberg R, Ravi V, Carmagnani Pestana R, Sen S, Subbiah VCancersUnique Aberrations in Intimal Sarcoma Identified by Next-Generation Sequencing as Potential Therapy Targets. Cancers (Basel). 2019 Aug 31; 11(9).Cancers (Basel)2019-08-31T00:00:002019Unique Aberrations in Intimal Sarcoma Identified by Next-Generation Sequencing as Potential Therapy Targets.Authorship 95510115Authorship 9557211331533818Habra MA, Stephen B, Campbell M, Hess K, Tapia C, Xu M, Rodon Ahnert J, Jimenez C, Lee JE, Perrier ND, Boraddus RR, Pant S, Subbiah V, Hong DS, Zarifa A, Fu S, Karp DD, Meric-Bernstam F, Naing AJournal for immunotherapy of cancerPhase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer. 2019 09 18; 7(1):253.J Immunother Cancer2019-09-18T00:00:002019Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma.Authorship 9578243Authorship 957841231648931Maxwell JE, Gule-Monroe MK, Subbiah V, Hu M, Perrier ND, Cabanillas ME, Lee JE, Graham PH, Cote GJ, Busaidy NL, Grubbs EGSurgeryNovel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (CDKN2C) loss assay in?sporadic medullary thyroid carcinoma. Surgery. 2020 01; 167(1):80-86.Surgery2019-10-21T00:00:002019Novel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (CDKN2C) loss assay in?sporadic medullary thyroid carcinoma.31650099Cuglievan B, Subbiah V, Wang H, Morani A, Meric-Bernstam F, Holla V, Herzog CEJCO precision oncologyResponse to Mammalian Target of Rapamycin-Based Therapy and Incidental Finding of Lynch Syndrome in a Patient With Solid Pseudopapillary Neoplasm of the Pancreas With AKT1_E17K Mutation. JCO Precis Oncol. 2018; 2.JCO Precis Oncol2018-12-19T00:00:002018Response to Mammalian Target of Rapamycin-Based Therapy and Incidental Finding of Lynch Syndrome in a Patient With Solid Pseudopapillary Neoplasm of the Pancreas With AKT1_E17K Mutation.Authorship 958022931658994Welsh JW, Tang C, de Groot P, Naing A, Hess KR, Heymach JV, Papadimitrakopoulou VA, Cushman TR, Subbiah V, Chang JY, Simon GR, Ramapriyan R, Barsoumian HB, Menon H, Cortez MA, Massarelli E, Nguyen Q, Sharma P, Allison JP, Diab A, Verma V, Raju U, Shaaban SG, Dadu R, Cabanillas ME, Wang K, Anderson C, Gomez DR, Hahn S, Komaki R, Hong DSCancer immunology researchPhase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. Cancer Immunol Res. 2019 12; 7(12):1903-1909.Cancer Immunol Res2019-10-28T00:00:002019Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses.Authorship 961479431758230Morani AC, Hanafy AK, Marcal LP, Subbiah V, Le O, Bathala TK, Elsayes KMAbdominal radiology (New York)Imaging of acute abdomen in cancer patients. Abdom Radiol (NY). 2020 08; 45(8):2287-2304.Abdom Radiol (NY)2020-08-01T00:00:002020Imaging of acute abdomen in cancer patients.Authorship 962019131792121Subbiah V, Pal SKCancer discoveryPrecision Oncology for Hepatocellular Cancer: Slivering the Liver by FGF19-FGF4-KLB Pathway Inhibition. Cancer Discov. 2019 12; 9(12):1646-1649.Cancer Discov2019-12-01T00:00:002019Precision Oncology for Hepatocellular Cancer: Slivering the Liver by FGF19-FGF4-KLB Pathway Inhibition.Authorship 9628071131852833Pairawan S, Hess KR, Janku F, Sanchez NS, Mills Shaw KR, Eng C, Damodaran S, Javle M, Kaseb AO, Hong DS, Subbiah V, Fu S, Fogelman DR, Raymond VM, Lanman RB, Meric-Bernstam FClinical cancer research : an official journal of the American Association for Cancer ResearchCell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. Clin Cancer Res. 2020 04 15; 26(8):1924-1931.Clin Cancer Res2019-12-18T00:00:002019Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer.Authorship 974996231886407Groisberg R, Subbiah VExpert review of precision medicine and drug developmentImmunotherapy and next-generation sequencing guided therapy for precision oncology: What have we learnt and what does the future hold? Expert Rev Precis Med Drug Dev. 2018; 3(3):205-213.Expert Rev Precis Med Drug Dev2018-06-18T00:00:002018Immunotherapy and next-generation sequencing guided therapy for precision oncology: What have we learnt and what does the future hold?Authorship 9757594Authorship 975971531951522Dickson D, Johnson J, Bergan R, Owens R, Subbiah V, Kurzrock RCellThe Master Observational Trial: A New Class of Master Protocol to Advance Precision Medicine. Cell. 2020 01 09; 180(1):9-14.Cell2020-01-09T00:00:002020The Master Observational Trial: A New Class of Master Protocol to Advance Precision Medicine.31935818Kairemo K, Santos EB, Macapinlac HA, Subbiah VDiagnostics (Basel, Switzerland)Early Response Assessment to Targeted Therapy Using 3'-deoxy-3'[(18)F]-Fluorothymidine (18F-FLT) PET/CT in Lung Cancer. Diagnostics (Basel). 2020 Jan 06; 10(1).Diagnostics (Basel)2020-01-06T00:00:002020Early Response Assessment to Targeted Therapy Using 3'-deoxy-3'[(18)F]-Fluorothymidine (18F-FLT) PET/CT in Lung Cancer.Authorship 976245631971821Narayanan S, Lazar Neto F, Tanco K, Lopez G, Liu W, Bruera E, Subbiah VJournal of alternative and complementary medicine (New York, N.Y.)Cannabidiol (CBD) Oil, Cancer, and Symptom Management: A Google Trends Analysis of Public Interest. J Altern Complement Med. 2020 Apr; 26(4):346-348.J Altern Complement Med2020-01-22T00:00:002020Cannabidiol (CBD) Oil, Cancer, and Symptom Management: A Google Trends Analysis of Public Interest.Authorship 9765711431988000Solomon BJ, Tan L, Lin JJ, Wong SQ, Hollizeck S, Ebata K, Tuch BB, Yoda S, Gainor JF, Sequist LV, Oxnard GR, Gautschi O, Drilon A, Subbiah V, Khoo C, Zhu EY, Nguyen M, Henry D, Condroski KR, Kolakowski GR, Gomez E, Ballard J, Metcalf AT, Blake JF, Dawson SJ, Blosser W, Stancato LF, Brandhuber BJ, Andrews S, Robinson BG, Rothenberg SMJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerRET Solvent Front Mutations Mediate Acquired?Resistance to Selective RET Inhibition in?RET-Driven Malignancies. J Thorac Oncol. 2020 04; 15(4):541-549.J Thorac Oncol2020-01-24T00:00:002020RET Solvent Front Mutations Mediate Acquired?Resistance to Selective RET Inhibition in?RET-Driven Malignancies.Authorship 977540132029534Subbiah V, Puzanov I, Blay JY, Chau I, Lockhart AC, Raje NS, Wolf J, Baselga J, Meric-Bernstam F, Roszik J, Diamond EL, Riely GJ, Sherman EJ, Riehl T, Pitcher B, Hyman DMCancer discoveryPan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers. Cancer Discov. 2020 05; 10(5):657-663.Cancer Discov2020-02-06T00:00:002020Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers.Authorship 97816310Authorship 978213132080210Wang Y, Janku F, Piha-Paul S, Hess K, Broaddus R, Liu L, Shi N, Overman M, Kopetz S, Subbiah V, Naing A, Hong D, Tsimberidou AM, Karp D, Yao J, Fu SScientific reportsPhase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. Sci Rep. 2020 02 20; 10(1):3080.Sci Rep2020-02-20T00:00:002020Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies.32083997Subbiah V, Yang D, Velcheti V, Drilon A, Meric-Bernstam FJournal of clinical oncology : official journal of the American Society of Clinical OncologyState-of-the-Art Strategies for Targeting RET-Dependent Cancers. J Clin Oncol. 2020 04 10; 38(11):1209-1221.J Clin Oncol2020-02-21T00:00:002020State-of-the-Art Strategies for Targeting RET-Dependent Cancers.Authorship 9784701Authorship 978556732094155Subbiah V, Cote GJCancer discoveryAdvances in Targeting RET-Dependent Cancers. Cancer Discov. 2020 04; 10(4):498-505.Cancer Discov2020-02-24T00:00:002020Advances in Targeting RET-Dependent Cancers.32101722Adashek JJ, Subbiah IM, Matos I, Garralda E, Menta AK, Ganeshan DM, Subbiah VTrends in cancerHyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact? Trends Cancer. 2020 03; 6(3):181-191.Trends Cancer2020-02-06T00:00:002020Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?Authorship 97937229Authorship 9795286Authorship 9797321332127467Groisberg R, Roszik J, Conley AP, Lazar AJ, Portal DE, Hong DS, Naing A, Herzog CE, Somaiah N, Zarzour MA, Patel S, Brown RE, Subbiah VMolecular cancer therapeuticsGenomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies. Mol Cancer Ther. 2020 05; 19(5):1165-1172.Mol Cancer Ther2020-03-03T00:00:002020Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies.32188704Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Habra MAJournal for immunotherapy of cancerPhase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020 03; 8(1).J Immunother Cancer2020-03-01T00:00:002020Phase 2 study of pembrolizumab in patients with advanced rare cancers.32197306Adashek JJ, Leonard A, Roszik J, Menta AK, Genovese G, Subbiah V, Msaouel PCancersCancer Genetics and Therapeutic Opportunities in Urologic Practice. Cancers (Basel). 2020 Mar 18; 12(3).Cancers (Basel)2020-03-18T00:00:002020Cancer Genetics and Therapeutic Opportunities in Urologic Practice.Authorship 9861191Authorship 986381532243791Dickson D, Johnson J, Bergan R, Owens R, Subbiah V, Kurzrock RCellSnapshot: Trial Types in Precision Medicine. Cell. 2020 04 02; 181(1):208-208.e1.Cell2020-04-02T00:00:002020Snapshot: Trial Types in Precision Medicine.32224306Trigo J, Subbiah V, Besse B, Moreno V, L?pez R, Sala MA, Peters S, Ponce S, Fern?ndez C, Alfaro V, G?mez J, Kahatt C, Zeaiter A, Zaman K, Boni V, Arrondeau J, Mart?nez M, Delord JP, Awada A, Kristeleit R, Olmedo ME, Wannesson L, Valdivia J, Rubio MJ, Anton A, Sarantopoulos J, Chawla SP, Mosquera-Martinez J, D'Arcangelo M, Santoro A, Villalobos VM, Sands J, Paz-Ares LThe Lancet. OncologyLurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 2020 05; 21(5):645-654.Lancet Oncol2020-03-27T00:00:002020Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.Authorship 987618732303572Anderson PM, Scott J, Parsai S, Zahler S, Worley S, Shrikanthan S, Subbiah V, Murphy EESMO open223-Radium for metastatic osteosarcoma: combination therapy with other agents and external beam radiotherapy. ESMO Open. 2020 04; 5(2).ESMO Open2020-04-01T00:00:002020223-Radium for metastatic osteosarcoma: combination therapy with other agents and external beam radiotherapy.Authorship 988128132337094Subbiah V, Dumbrava EI, Jiang Y, Thein KZ, Naing A, Hong DS, Fu S, Piha-Paul SA, Tsimberidou AM, Janku F, Meric-Bernstam F, Kurzrock R, Falchook GExperimental hematology & oncologyDual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. Exp Hematol Oncol. 2020; 9:7.Exp Hematol Oncol2020-04-20T00:00:002020Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial.Authorship 988702332368727Alhalabi O, Iyer S, Subbiah VEClinicalMedicineTesting for COVID-19 in patients with cancer. EClinicalMedicine. 2020 Jun; 23:100374.EClinicalMedicine2020-05-03T00:00:002020Testing for COVID-19 in patients with cancer.Authorship 989156232386875Alhalabi O, Subbiah VTrends in cancerManaging Cancer Care during the COVID-19 Pandemic and Beyond. Trends Cancer. 2020 07; 6(7):533-535.Trends Cancer2020-04-27T00:00:002020Managing Cancer Care during the COVID-19 Pandemic and Beyond.Authorship 991918132540454Subbiah V, Baik C, Kirkwood JMTrends in cancerClinical Development of BRAF plus MEK Inhibitor Combinations. Trends Cancer. 2020 09; 6(9):797-810.Trends Cancer2020-06-13T00:00:002020Clinical Development of BRAF plus MEK Inhibitor Combinations.Authorship 993709532630797Amin HM, Morani AC, Daw NC, Lamhamedi-Cherradi SE, Subbiah V, Menegaz BA, Vishwamitra D, Eskandari G, George B, Benjamin RS, Patel S, Song J, Lazar AJ, Wang WL, Kurzrock R, Pappo A, Anderson PM, Schwartz GK, Araujo D, Cuglievan B, Ratan R, McCall D, Mohiuddin S, Livingston JA, Molina ER, Naing A, Ludwig JACancersIGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers. Cancers (Basel). 2020 Jul 02; 12(7).Cancers (Basel)2020-07-02T00:00:002020IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers.Authorship 994385532665298Belli C, Anand S, Gainor JF, Penault-Llorca F, Subbiah V, Drilon A, Andr? F, Curigliano GClinical cancer research : an official journal of the American Association for Cancer ResearchProgresses Toward Precision Medicine in RET-altered Solid Tumors. Clin Cancer Res. 2020 12 01; 26(23):6102-6111.Clin Cancer Res2020-07-14T00:00:002020Progresses Toward Precision Medicine in RET-altered Solid Tumors.Authorship 9951341332702645Pasalic D, McGinnis GJ, Fuller CD, Grossberg AJ, Verma V, Mainwaring W, Miller AB, Lin TA, Jethanandani A, Espinoza AF, Diefenhardt M, Das P, Subbiah V, Subbiah IM, Jagsi R, Garden AS, Fokas E, R?del C, Thomas CR, Minsky BD, Ludmir EBEuropean journal of cancer (Oxford, England : 1990)Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials. Eur J Cancer. 2020 09; 136:176-185.Eur J Cancer2020-07-20T00:00:002020Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials.Authorship 9966881Authorship 996746732771306Subbiah V, Solit DB, Chan TA, Kurzrock RAnnals of oncology : official journal of the European Society for Medical OncologyThe FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) =10: a decision centered on empowering patients and their physicians. Ann Oncol. 2020 09; 31(9):1115-1118.Ann Oncol2020-08-05T00:00:002020The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) =10: a decision centered on empowering patients and their physicians.32775947Hegde A, Hong DS, Behrang A, Ali SM, Juckett L, Meric-Bernstam F, Subbiah VJCO precision oncologyActivity of Brigatinib in Crizotinib and Ceritinib-Resistant ROS1- Rearranged Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2019; 3.JCO Precis Oncol2019-02-15T00:00:002019Activity of Brigatinib in Crizotinib and Ceritinib-Resistant ROS1- Rearranged Non-Small-Cell Lung Cancer.Authorship 9974431Authorship 9974607Authorship 9974781Authorship 997582232816889Subbiah V, Erwin W, Mawlawi O, McCoy A, Wages D, Wheeler C, Gonzalez-Lepera C, Liu H, Macapinlac H, Meric-Bernstam F, Hong DS, Pant S, Le D, Santos E, Gonzalez J, Roszik J, Suzuki T, Subach RA, Madden T, Johansen M, Nomura F, Satoh H, Matsuura T, Kajita M, Nakamura E, Funase Y, Matsushima S, Ravizzini GClinical cancer research : an official journal of the American Association for Cancer ResearchPhase I Study of P-cadherin-targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors. Clin Cancer Res. 2020 11 15; 26(22):5830-5842.Clin Cancer Res2020-08-18T00:00:002020Phase I Study of P-cadherin-targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors.32817069Anand K, Sahu G, Burns E, Ensor A, Ensor J, Pingali SR, Subbiah V, Iyer SPESMO openMycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors. ESMO Open. 2020 08; 5(4).ESMO Open2020-08-01T00:00:002020Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors.32818466Subbiah V, Lassen U, ?lez E, Italiano A, Curigliano G, Javle M, de Braud F, Prager GW, Greil R, Stein A, Fasolo A, Schellens JHM, Wen PY, Viele K, Boran AD, Gasal E, Burgess P, Ilankumaran P, Wainberg ZAThe Lancet. OncologyDabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 2020 09; 21(9):1234-1243.Lancet Oncol2020-08-17T00:00:002020Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.32824391Jimenez C, Subbiah V, Stephen B, Ma J, Milton D, Xu M, Zarifa A, Akhmedzhanov FO, Tsimberidou A, Habra MA, Rodon Anhert J, Fu S, Naing ACancersPhase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas. Cancers (Basel). 2020 Aug 16; 12(8).Cancers (Basel)2020-08-16T00:00:002020Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas.Authorship 99799210Authorship 99804045Authorship 9980433932843426Sen S, Tanaka R, Khatua S, Zaky W, Janku F, Penas-Prado M, Weathers SP, Behrang A, Roszik J, Subbiah VCold Spring Harbor molecular case studiesDual inhibition of BRAF and mTOR in BRAFV600E -mutant pediatric, adolescent, and young adult brain tumors. Cold Spring Harb Mol Case Stud. 2020 08; 6(4).Cold Spring Harb Mol Case Stud2020-08-25T00:00:002020Dual inhibition of BRAF and mTOR in BRAFV600E -mutant pediatric, adolescent, and young adult brain tumors.32846060Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, McCoach CE, Gautschi O, Besse B, Cho BC, Peled N, Weiss J, Kim YJ, Ohe Y, Nishio M, Park K, Patel J, Seto T, Sakamoto T, Rosen E, Shah MH, Barlesi F, Cassier PA, Bazhenova L, De Braud F, Garralda E, Velcheti V, Satouchi M, Ohashi K, Pennell NA, Reckamp KL, Dy GK, Wolf J, Solomon B, Falchook G, Ebata K, Nguyen M, Nair B, Zhu EY, Yang L, Huang X, Olek E, Rothenberg SM, Goto K, Subbiah VThe New England journal of medicineEfficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2020 08 27; 383(9):813-824.N Engl J Med2020-08-27T00:00:002020Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.32846061Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, Worden F, Brose M, Patel J, Leboulleux S, Godbert Y, Barlesi F, Morris JC, Owonikoko TK, Tan DSW, Gautschi O, Weiss J, de la Fouchardi?re C, Burkard ME, Laskin J, Taylor MH, Kroiss M, Medioni J, Goldman JW, Bauer TM, Levy B, Zhu VW, Lakhani N, Moreno V, Ebata K, Nguyen M, Heirich D, Zhu EY, Huang X, Yang L, Kherani J, Rothenberg SM, Drilon A, Subbiah V, Shah MH, Cabanillas METhe New England journal of medicineEfficacy of Selpercatinib in RET-Altered Thyroid Cancers. N Engl J Med. 2020 08 27; 383(9):825-835.N Engl J Med2020-08-27T00:00:002020Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.Authorship 99899113Authorship 9993251Authorship 9993324Authorship 9993401Authorship 99951015Authorship 9995171032923865Dumbrava EEI, Balaji K, Raghav K, Hess K, Javle M, Blum-Murphy M, Ajani J, Kopetz S, Broaddus R, Routbort M, Demirhan M, Zheng X, Pant S, Tsimberidou AM, Subbiah V, Hong DS, Rodon J, Shaw KM, Piha-Paul SA, Meric-Bernstam FJCO precision oncologyTargeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications. JCO Precis Oncol. 2019; 3.JCO Precis Oncol2019-10-21T00:00:002019Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications.32923868S?nchez NS, Kahle MP, Bailey AM, Wathoo C, Balaji K, Demirhan ME, Yang D, Javle M, Kaseb A, Eng C, Subbiah V, Janku F, Raymond VM, Lanman RB, Mills Shaw KR, Meric-Bernstam FJCO precision oncologyIdentification of Actionable Genomic Alterations Using Circulating Cell-Free DNA. JCO Precis Oncol. 2019; 3.JCO Precis Oncol2019-09-24T00:00:002019Identification of Actionable Genomic Alterations Using Circulating Cell-Free DNA.32947844Lin TA, Fuller CD, Verma V, Mainwaring W, Espinoza AF, Miller AB, Jethanandani A, Pasalic D, Das P, Minsky BD, Thomas CR, Fogelman DR, Subbiah V, Subbiah IM, Ludmir EBCancersTrial Sponsorship and Time to Reporting for Phase 3 Randomized Cancer Clinical Trials. Cancers (Basel). 2020 Sep 16; 12(9).Cancers (Basel)2020-09-16T00:00:002020Trial Sponsorship and Time to Reporting for Phase 3 Randomized Cancer Clinical Trials.32913986Subbiah V, Sen S, Hess KR, Janku F, Hong DS, Khatua S, Karp DD, Munoz J, Falchook GS, Groisberg R, Tsimberidou AM, Sherman SI, Hwu P, Meric-Bernstam FJCO precision oncologyPhase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies. JCO Precis Oncol. 2018; 2.JCO Precis Oncol2018-09-13T00:00:002018Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies.32914012Carmagnani Pestana R, Groisberg R, Roszik J, Subbiah VJCO precision oncologyPrecision Oncology in Sarcomas: Divide and Conquer. JCO Precis Oncol. 2019; 3.JCO Precis Oncol2019-04-25T00:00:002019Precision Oncology in Sarcomas: Divide and Conquer.32914022Subbiah V, Gervais R, Riely G, Hollebecque A, Blay JY, Felip E, Schuler M, Gon?alves A, Italiano A, Keedy V, Chau I, Puzanov I, Raje NS, Meric-Bernstam F, Makrutzki M, Riehl T, Pitcher B, Baselga J, Hyman DMJCO precision oncologyEfficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With BRAF V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study. JCO Precis Oncol. 2019; 3.JCO Precis Oncol2019-06-27T00:00:002019Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With BRAF V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study.Authorship 1000831233008795Adashek JJ, Subbiah V, Kurzrock RTrends in cancerFrom Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm. Trends Cancer. 2021 01; 7(1):15-28.Trends Cancer2020-09-29T00:00:002020From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm.Authorship 10020634Authorship 1002352233012364Abi Jaoude J, Kouzy R, El Alam MB, Subbiah V, Taniguchi CM, Ludmir EB, Lin TAMayo Clinic proceedingsExclusion of Older Adults in COVID-19 Clinical Trials. Mayo Clin Proc. 2020 10; 95(10):2293-2294.Mayo Clin Proc2020-08-14T00:00:002020Exclusion of Older Adults in COVID-19 Clinical Trials.33035458Groisberg R, Subbiah VThe Lancet. OncologyEZH2 inhibition for epithelioid sarcoma and follicular lymphoma. Lancet Oncol. 2020 11; 21(11):1388-1390.Lancet Oncol2020-10-06T00:00:002020EZH2 inhibition for epithelioid sarcoma and follicular lymphoma.Authorship 10027652Authorship 1002842633049750Groisberg R, Subbiah VOncologySequencing PEComas: Viewing Unicorns through the Molecular Looking Glass. Oncology. 2021; 99(1):62-64.Oncology2020-10-13T00:00:002020Sequencing PEComas: Viewing Unicorns through the Molecular Looking Glass.33055173Janku F, Park H, Call SG, Madwani K, Oki Y, Subbiah V, Hong DS, Naing A, Velez-Bravo VM, Barnes TG, Hagemeister FB, Falchook GS, Karp DD, Wheler JJ, Piha-Paul SA, Garrido-Laguna I, Shpall EJ, Fayad LE, Neelapu SS, Meric-Bernstam F, Kurzrock R, Fanale MAClinical cancer research : an official journal of the American Association for Cancer ResearchSafety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. Clin Cancer Res. 2020 11 01; 26(21):5579-5587.Clin Cancer Res2020-10-14T00:00:002020Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma.Authorship 10034311Authorship 100345619Authorship 100347122Authorship 10035842Authorship 1003683933096421Subbiah V, Paz-Ares L, Besse B, Moreno V, Peters S, Sala MA, L?pez-Vilari?o JA, Fern?ndez C, Kahatt C, Alfaro V, Siguero M, Zeaiter A, Zaman K, L?pez R, Ponce S, Boni V, Arrondeau J, Delord JP, Mart?nez M, Wannesson L, Ant?n A, Valdivia J, Awada A, Kristeleit R, Olmedo ME, Rubio MJ, Sarantopoulos J, Chawla SP, Mosquera-Martinez J, D' Arcangelo M, Santoro A, Villalobos VM, Sands J, Trigo JLung cancer (Amsterdam, Netherlands)Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. Lung Cancer. 2020 12; 150:90-96.Lung Cancer2020-10-10T00:00:002020Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment.33097611Mendoza T, Sheshadri A, Altan M, Hess K, George G, Stephen B, Castillo L, Rodriguez E, Gong J, Peterson C, Rodon Ahnert J, Fu S, Piha-Paul SA, Pant S, Dumbrava E, Yap TA, Janku F, Tsimberidou AM, Subbiah V, Karp DD, Zarifa A, McQuinn LM, Cleeland C, Hong DS, Naing AJournal for immunotherapy of cancerEvaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory. J Immunother Cancer. 2020 10; 8(2).J Immunother Cancer2020-10-01T00:00:002020Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory.33097651Hegde A, Andreev-Drakhlin AY, Roszik J, Huang L, Liu S, Hess K, Cabanillas M, Hu MI, Busaidy NL, Sherman SI, Dadu R, Grubbs EG, Ali SM, Lee J, Elamin YY, Simon GR, Blumenschein GR, Papadimitrakopoulou VA, Hong D, Meric-Bernstam F, Heymach J, Subbiah VESMO openResponsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies. ESMO Open. 2020 10; 5(5):e000799.ESMO Open2020-10-01T00:00:002020Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies.33108504Fudio S, Tabernero J, Subbiah V, Chawla SP, Moreno V, Longo F, Lopez R, Anton A, Trigo JM, Shapiro G, Jeong W, Villalobos VM, Lubomirov R, Fernandez-Teruel C, Alfaro V, Boni VCancer chemotherapy and pharmacologyEffect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysis. Cancer Chemother Pharmacol. 2021 01; 87(1):113-124.Cancer Chemother Pharmacol2020-10-27T00:00:002020Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysis.33115815Ballhausen A, Wheler JJ, Karp DD, Piha-Paul SA, Fu S, Pant S, Tsimberidou AM, Hong DS, Subbiah V, Holley VR, Huang HJ, Brewster AM, Koenig KB, Ibrahim NK, Meric-Bernstam F, Janku FClinical cancer research : an official journal of the American Association for Cancer ResearchPhase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-positive Metastatic Breast Cancer or Other Solid Tumors. Clin Cancer Res. 2021 03 01; 27(5):1247-1255.Clin Cancer Res2020-10-28T00:00:002020Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-positive Metastatic Breast Cancer or Other Solid Tumors.Authorship 10045311Authorship 10045524Authorship 10045714Authorship 10046701Authorship 100477212Authorship 10055801533161056Subbiah V, Shen T, Terzyan SS, Liu X, Hu X, Patel KP, Hu M, Cabanillas M, Behrang A, Meric-Bernstam F, Vo PTT, Mooers BHM, Wu JAnnals of oncology : official journal of the European Society for Medical OncologyStructural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. Ann Oncol. 2021 02; 32(2):261-268.Ann Oncol2020-11-05T00:00:002020Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.33169506Jozaghi Y, Zafereo M, Williams MD, Gule-Monroe MK, Wang J, Grubbs EG, Vaporciyan A, Hu MI, Busaidy N, Dadu R, Waguespack SG, Subbiah V, Cabanillas MHead & neckNeoadjuvant selpercatinib for advanced medullary thyroid cancer. Head Neck. 2021 01; 43(1):E7-E12.Head Neck2020-11-09T00:00:002020Neoadjuvant selpercatinib for advanced medullary thyroid cancer.33152307Subbiah V, Lassen U, Gasal E, Burgess P, Wainberg ZAThe Lancet. OncologyDabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer - Authors' reply. Lancet Oncol. 2020 11; 21(11):e516.Lancet Oncol2020-11-01T00:00:002020Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer - Authors' reply.33153645Norris DC, Sen S, Groisberg R, Subbiah VMayo Clinic proceedingsPatient-Centered, Physician-Investigator Friendly Pragmatic Phase Trial Designs-The 4P Model. Mayo Clin Proc. 2020 11; 95(11):2566-2568.Mayo Clin Proc2020-11-01T00:00:002020Patient-Centered, Physician-Investigator Friendly Pragmatic Phase Trial Designs-The 4P Model.33154983Andreev-Drakhlin A, Cabanillas M, Amini B, Subbiah VJCO precision oncologySystemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases. JCO Precis Oncol. 2020; 4.JCO Precis Oncol2020-10-30T00:00:002020Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases.33229506Hahn AW, Alhalabi O, Msaouel P, Meric-Bernstam F, Naing A, Jonasch E, Piha-Paul S, Hong D, Pant S, Yap T, Campbell E, Le H, Tannir NM, Roszik J, Subbiah VESMO openValidation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials. ESMO Open. 2020 11; 5(6):e001073.ESMO Open2020-11-01T00:00:002020Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials.Authorship 10069352233323389Alhalabi O, Hahn AW, Msaouel P, Andreev-Drakhlin AY, Meric-Bernstam F, Naing A, Piha-Paul S, Filip J, Pant S, Yap TA, Hong DS, Fu S, Karp D, Campbell E, Le H, Campbell MT, Shah AY, Tannir NM, Siefker-Radtke AO, Gao J, Roszik J, Subbiah VMolecular cancer research : MCRMolecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. Mol Cancer Res. 2021 03; 19(3):395-402.Mol Cancer Res2020-12-15T00:00:002020Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes.Authorship 1007572433386907Ganeshan D, Kambadakone A, Nikolaidis P, Subbiah V, Subbiah IM, Devine CAbdominal radiology (New York)Current update on gallbladder carcinoma. Abdom Radiol (NY). 2021 06; 46(6):2474-2489.Abdom Radiol (NY)2021-01-02T00:00:002021Current update on gallbladder carcinoma.Authorship 1008458933415580How JA, Jazaeri A, Westin SN, Sood AK, Ramondetta LM, Xu M, Abonofal A, Karp DD, Subbiah V, Stephen B, Rodon JA, Yang F, Naing AInvestigational new drugsThe clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial. Invest New Drugs. 2021 06; 39(3):829-835.Invest New Drugs2021-01-07T00:00:002021The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial.Authorship 1009877333491277Tsimberidou AM, Vo HH, Subbiah V, Janku F, Piha-Paul S, Yilmaz B, Gong J, Naqvi MF, Tu SM, Campbell M, Meric-Bernstam F, Naing AThe oncologistPembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors. Oncologist. 2021 07; 26(7):558-e1098.Oncologist2021-02-12T00:00:002021Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors.Authorship 10119157Authorship 10121401Authorship 1012878333608377Luke JJ, Barlesi F, Chung K, Tolcher AW, Kelly K, Hollebecque A, Le Tourneau C, Subbiah V, Tsai F, Kao S, Cassier PA, Khasraw M, Kindler HL, Fang H, Fan F, Allaire K, Patel M, Ye S, Chao DT, Henner WR, Hayflick JS, McDevitt MA, Fong LJournal for immunotherapy of cancerPhase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. J Immunother Cancer. 2021 02; 9(2).J Immunother Cancer2021-02-01T00:00:002021Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors.33617938Subbiah V, Shen T, Tetzlaff M, Weissferdt A, Byers LA, Cascone T, Behrang A, Meric-Bernstam F, Mooers BHM, Rothenberg SM, Ebata K, Wu JAnnals of oncology : official journal of the European Society for Medical OncologyPatient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer. Ann Oncol. 2021 06; 32(6):817-819.Ann Oncol2021-02-20T00:00:002021Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer.33674736Yao S, Janku F, Subbiah V, Stewart J, Patel SP, Kaseb A, Westin SN, Naing A, Tsimberidou AM, Hong D, Piha-Paul SA, Shi N, Johnston A, Bomalaski J, Fu SBritish journal of cancerPhase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies. Br J Cancer. 2021 04; 124(9):1533-1539.Br J Cancer2021-03-05T00:00:002021Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies.Authorship 1013597233707180Groisberg R, Subbiah VClinical cancer research : an official journal of the American Association for Cancer ResearchCombination Therapies for Precision Oncology: The Ultimate Whack-A-Mole Game. Clin Cancer Res. 2021 05 15; 27(10):2672-2674.Clin Cancer Res2021-03-11T00:00:002021Combination Therapies for Precision Oncology: The Ultimate Whack-A-Mole Game.Authorship 101387423Authorship 10139204Authorship 1014171833723371Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, Dragovich T, Matrana M, Agarwal N, Chawla S, Kato S, Morgan G, Kasi PM, Solomon B, Loong HH, Park H, Choueiri TK, Subbiah IM, Pemmaraju N, Subbiah V, COVID19 and Cancer Clinical Trials Working GroupNature reviews. Clinical oncologyCOVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nat Rev Clin Oncol. 2021 05; 18(5):313-319.Nat Rev Clin Oncol2021-03-15T00:00:002021COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials.33728727Al-Zubidi N, Gombos DS, Hong DS, Subbiah V, Fu S, Ahnert JR, Piha-Paul SA, Tsimberidou AM, Karp DD, Bernstam FM, Naing AThe oncologistOverview of Ocular Side Effects of Selinexor. Oncologist. 2021 07; 26(7):619-623.Oncologist2021-04-08T00:00:002021Overview of Ocular Side Effects of Selinexor.33742104Tsimberidou AM, Hong DS, Fu S, Karp DD, Piha-Paul S, Kies MS, Ravi V, Subbiah V, Patel SM, Tu SM, Janku F, Heymach J, Johnson A, Cartwright C, Zhao L, Zhang J, Berry DA, Vining DJ, Futreal A, Miller VA, Meric-Bernstam FNPJ precision oncologyPrecision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. NPJ Precis Oncol. 2021 Mar 19; 5(1):21.NPJ Precis Oncol2021-03-19T00:00:002021Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study.Authorship 101444623Authorship 10146321133771853Hegde A, Jayaprakash P, Couillault CA, Piha-Paul S, Karp D, Rodon J, Pant S, Fu S, Dumbrava EE, Yap TA, Subbiah V, Bhosale P, Coarfa C, Higgins JP, Williams ET, Wilson TF, Lim J, Meric-Bernstam F, Sumner E, Zain H, Nguyen D, Nguyen LM, Rajapakshe K, Curran MA, Hong DSClinical cancer research : an official journal of the American Association for Cancer ResearchA Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies. Clin Cancer Res. 2021 06 01; 27(11):3050-3060.Clin Cancer Res2021-03-26T00:00:002021A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies.33758378Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, Dragovich T, Matrana M, Agarwal N, Chawla S, Kato S, Morgan G, Kasi PM, Solomon B, Loong HH, Park H, Choueiri TK, Subbiah IM, Pemmaraju N, Subbiah V, COVID19 and Cancer Clinical Trials Working GroupNature reviews. Clinical oncologyAuthor Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nat Rev Clin Oncol. 2021 May; 18(5):320.Nat Rev Clin Oncol2021-05-01T00:00:002021Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials.Authorship 10150546Authorship 101550310Authorship 1015761533820780Demetri GD, Luke JJ, Hollebecque A, Powderly JD, Spira AI, Subbiah V, Naumovski L, Chen C, Fang H, Lai DW, Yue H, Polepally AR, Purcell JW, Robinson R, Sharma P, Allison JP, Tolcher A, Villalobos VMClinical cancer research : an official journal of the American Association for Cancer ResearchFirst-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors. Clin Cancer Res. 2021 07 01; 27(13):3556-3566.Clin Cancer Res2021-04-05T00:00:002021First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors.33783054Huey RW, George GC, Phillips P, White R, Fu S, Janku F, Karp DD, Naing A, Piha-Paul S, Subbiah V, Tsimberidou AM, Pant S, Yap TA, Rodon J, Meric-Bernstam F, Shih YT, Hong DSThe oncologistPatient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials. Oncologist. 2021 07; 26(7):588-596.Oncologist2021-04-21T00:00:002021Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials.33798954Addeo A, Passaro A, Malapelle U, Banna GL, Subbiah V, Friedlaender ACancer treatment reviewsImmunotherapy in non-small cell lung cancer harbouring driver mutations. Cancer Treat Rev. 2021 05; 96:102179.Cancer Treat Rev2021-03-19T00:00:002021Immunotherapy in non-small cell lung cancer harbouring driver mutations.Authorship 10162701433849924Colen RR, Rolfo C, Ak M, Ayoub M, Ahmed S, Elshafeey N, Mamindla P, Zinn PO, Ng C, Vikram R, Bakas S, Peterson CB, Rodon Ahnert J, Subbiah V, Karp DD, Stephen B, Hajjar J, Naing AJournal for immunotherapy of cancerRadiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers. J Immunother Cancer. 2021 04; 9(4).J Immunother Cancer2021-04-01T00:00:002021Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers.Authorship 10171821333909232Thein KZ, Piha-Paul SA, Tsimberidou A, Karp DD, Janku F, Zarifa A, Shah J, Milton DR, Bean S, McQuinn L, Gong J, Colen R, Carter BW, Subbiah V, Ogbonna DC, Pant S, Meric-Bernstam F, Naing AInvestigational new drugsSelinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study. Invest New Drugs. 2021 10; 39(5):1357-1365.Invest New Drugs2021-04-28T00:00:002021Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study.Authorship 1018681733994796Piha-Paul SA, Dumbrava EE, Nair BC, Xiong W, Xu L, Mostorino R, Subbiah V, Tannir N, Fu S, Naing A, Janku F, Karp DD, Patel S, Daw NC, Hong D, Meric-Bernstam F, Zinner ROncoTargets and therapyA Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies. Onco Targets Ther. 2021; 14:3037-3049.Onco Targets Ther2021-05-07T00:00:002021A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies.Authorship 1020301134088726Subbiah V, Gainor JF, Oxnard GR, Tan DSW, Owen DH, Cho BC, Loong HH, McCoach CE, Weiss J, Kim YJ, Bazhenova L, Park K, Daga H, Besse B, Gautschi O, Rolfo C, Zhu EY, Kherani JF, Huang X, Kang S, Drilon AClinical cancer research : an official journal of the American Association for Cancer ResearchIntracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial. Clin Cancer Res. 2021 08 01; 27(15):4160-4167.Clin Cancer Res2021-06-04T00:00:002021Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial.Authorship 1020656434099825Shen T, Hu X, Liu X, Subbiah V, Mooers BHM, Wu JNPJ precision oncologyThe L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib. NPJ Precis Oncol. 2021 Jun 07; 5(1):48.NPJ Precis Oncol2021-06-07T00:00:002021The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib.Authorship 102104424Authorship 10210461Authorship 10210611134118197Gainor JF, Curigliano G, Kim DW, Lee DH, Besse B, Baik CS, Doebele RC, Cassier PA, Lopes G, Tan DSW, Garralda E, Paz-Ares LG, Cho BC, Gadgeel SM, Thomas M, Liu SV, Taylor MH, Mansfield AS, Zhu VW, Clifford C, Zhang H, Palmer M, Green J, Turner CD, Subbiah VThe Lancet. OncologyPralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncol. 2021 07; 22(7):959-969.Lancet Oncol2021-06-09T00:00:002021Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.34118198Subbiah V, Hu MI, Wirth LJ, Schuler M, Mansfield AS, Curigliano G, Brose MS, Zhu VW, Leboulleux S, Bowles DW, Baik CS, Adkins D, Keam B, Matos I, Garralda E, Gainor JF, Lopes G, Lin CC, Godbert Y, Sarker D, Miller SG, Clifford C, Zhang H, Turner CD, Taylor MHThe lancet. Diabetes & endocrinologyPralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol. 2021 08; 9(8):491-501.Lancet Diabetes Endocrinol2021-06-09T00:00:002021Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.34118915Abi Jaoude J, Kouzy R, Ghabach M, Patel R, Pasalic D, Ghossain E, Miller AB, Lin TA, Verma V, Fuller CD, Subbiah V, Minsky BD, Ludmir EB, Taniguchi CMBMC cancerFood and Drug Administration approvals in phase 3 Cancer clinical trials. BMC Cancer. 2021 Jun 12; 21(1):695.BMC Cancer2021-06-12T00:00:002021Food and Drug Administration approvals in phase 3 Cancer clinical trials.Authorship 1023595134242968Subbiah V, Kuravi S, Ganguly S, Welch DR, Vivian CJ, Mushtaq MU, Hegde A, Iyer S, Behrang A, Ali SM, Madison RW, Venstrom JM, Jensen RA, McGuirk JP, Amin HM, Balusu RESMO openPrecision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma. ESMO Open. 2021 08; 6(4):100172.ESMO Open2021-07-07T00:00:002021Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma.Authorship 10263081434315823Colen RR, Rolfo C, Ak M, Ayoub M, Ahmed S, Elshafeey N, Mamindla P, Zinn PO, Ng C, Vikram R, Bakas S, Peterson CB, Rodon Ahnert J, Subbiah V, Karp DD, Stephen B, Hajjar J, Naing AJournal for immunotherapy of cancerAuthor response to Cunha et al. J Immunother Cancer. 2021 07; 9(7).J Immunother Cancer2021-07-01T00:00:002021Author response to Cunha et al.Authorship 10269212334362693Alhalabi O, Hahn AW, Msaouel P, Meric-Bernstam F, Wilson N, Naing A, Piha-Paul S, Janku F, Pant S, Yap TA, Hong DS, Fu S, Karp D, Beltran K, Campbell E, Le H, Campbell MT, Shah A, Tannir NM, Siefker-Radtke A, Gao J, Roszik J, Subbiah VClinical genitourinary cancerValidation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. Clin Genitourin Cancer. 2022 02; 20(1):e16-e24.Clin Genitourin Cancer2021-07-12T00:00:002021Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials.Authorship 1027804534391699Thein KZ, Velcheti V, Mooers BHM, Wu J, Subbiah VTrends in cancerPrecision therapy for RET-altered cancers with RET inhibitors. Trends Cancer. 2021 12; 7(12):1074-1088.Trends Cancer2021-08-12T00:00:002021Precision therapy for RET-altered cancers with RET inhibitors.Authorship 10288433Authorship 1028946434476331Hendifar A, Blais EM, Wolpin B, Subbiah V, Collisson E, Singh I, Cannon T, Shaw K, Petricoin EF, Klempner S, Lyons E, Wang-Gillam A, Pishvaian MJ, O'Reilly EMJCO precision oncologyRetrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies. JCO Precis Oncol. 2021; 5.JCO Precis Oncol2021-08-25T00:00:002021Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies.34468905Kato S, Adashek JJ, Subbiah V, Fu S, Sun M, Nguyen L, Brown EJ, Yap TA, Karp DD, Piha-Paul SA, Hong DSInvestigational new drugsA phase i study of ixazomib and erlotinib in patients with advanced solid tumors. Invest New Drugs. 2022 02; 40(1):99-105.Invest New Drugs2021-09-01T00:00:002021A phase i study of ixazomib and erlotinib in patients with advanced solid tumors.Authorship 1029269634493590Adashek JJ, Desai AP, Andreev-Drakhlin AY, Roszik J, Cote GJ, Subbiah VMolecular cancer therapeuticsHallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers. Mol Cancer Ther. 2021 10; 20(10):1769-1776.Mol Cancer Ther2021-09-06T00:00:002021Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers.Authorship 10296293Authorship 102964310Authorship 10296743Authorship 10297366Authorship 1029753434518310Atrafi F, Boix O, Subbiah V, Diamond JR, Chawla SP, Tolcher AW, LoRusso PM, Eder JP, Gutierrez M, Sankhala K, Rajagopalan P, Genvresse I, Langer S, Mathijssen RHJ, Verweij J, Bruns I, Lolkema MPClinical cancer research : an official journal of the American Association for Cancer ResearchA Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation. Clin Cancer Res. 2021 12 01; 27(23):6366-6375.Clin Cancer Res2021-09-13T00:00:002021A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation.34516023Wirth LJ, Robinson B, Boni V, Tan DSW, McCoach C, Massarelli E, Hess LM, Jen MH, Kherani J, Olek E, Subbiah VThe oncologistPatient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial. Oncologist. 2022 02 03; 27(1):13-21.Oncologist2022-02-03T00:00:002022Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial.34515215Sch?ffski P, Concin N, Suarez C, Subbiah V, Ando Y, Ruan S, Wagner JP, Mansfield K, Zhu X, Origuchi S, DiDominick S, Bialucha CU, Faris JE, Tran BOncology research and treatmentA Phase 1 Study of a CDH6-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors with Evaluation of Inflammatory and Neurological Adverse Events. Oncol Res Treat. 2021; 44(10):547-556.Oncol Res Treat2021-08-19T00:00:002021A Phase 1 Study of a CDH6-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors with Evaluation of Inflammatory and Neurological Adverse Events.34521405Ramagopalan S, Leahy TP, Ray J, Wilkinson S, Sammon C, Subbiah VBMC medicineThe value of innovation: association between improvements in survival of advanced and metastatic non-small cell lung cancer and targeted and immunotherapy. BMC Med. 2021 09 15; 19(1):209.BMC Med2021-09-15T00:00:002021The value of innovation: association between improvements in survival of advanced and metastatic non-small cell lung cancer and targeted and immunotherapy.34523767Minchom A, Tan AC, Massarelli E, Subbiah V, Boni V, Robinson B, Wirth LJ, Hess LM, Jen MH, Kherani J, Olek E, McCoach CEThe oncologistPatient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-Small Cell Lung Cancer in the Phase I/II LIBRETTO-001 Trial. Oncologist. 2022 02 03; 27(1):22-29.Oncologist2022-02-03T00:00:002022Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-Small Cell Lung Cancer in the Phase I/II LIBRETTO-001 Trial.Authorship 1030351234561632Friedlaender A, Subbiah V, Russo A, Banna GL, Malapelle U, Rolfo C, Addeo ANature reviews. Clinical oncologyEGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment. Nat Rev Clin Oncol. 2022 01; 19(1):51-69.Nat Rev Clin Oncol2021-09-24T00:00:002021EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment.Authorship 10310832Authorship 10311531034611336Friedlaender A, Subbiah V, Russo A, Banna GL, Malapelle U, Rolfo C, Addeo ANature reviews. Clinical oncologyAuthor Correction: EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment. Nat Rev Clin Oncol. 2022 Jan; 19(1):70.Nat Rev Clin Oncol2022-01-01T00:00:002022Author Correction: EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment.34618040Wilkinson S, Gupta A, Scheuer N, Mackay E, Arora P, Thorlund K, Wasiak R, Ray J, Ramagopalan S, Subbiah VJAMA network openAssessment of Alectinib vs Ceritinib in ALK-Positive Non-Small Cell Lung Cancer in Phase 2 Trials and in Real-world Data. JAMA Netw Open. 2021 10 01; 4(10):e2126306.JAMA Netw Open2021-10-01T00:00:002021Assessment of Alectinib vs Ceritinib in ALK-Positive Non-Small Cell Lung Cancer in Phase 2 Trials and in Real-world Data.Authorship 10319236Authorship 1031991634680396Roszik J, Mustachio LM, Livingston JA, Groisberg R, Carmagnani Pestana R, Subbiah V, Conley APCancersLandscape of Immune-Related Markers and Potential Therapeutic Targets in Soft Tissue Sarcoma. Cancers (Basel). 2021 Oct 19; 13(20).Cancers (Basel)2021-10-19T00:00:002021Landscape of Immune-Related Markers and Potential Therapeutic Targets in Soft Tissue Sarcoma.34656365Pestana RC, Roszik J, Groisberg R, Sen S, Van Tine BA, Conley AP, Subbiah VCurrent problems in cancerDiscovery of targeted expression data for novel antibody-based and chimeric antigen receptor-based therapeutics in soft tissue sarcomas using RNA-sequencing: clinical implications. Curr Probl Cancer. 2021 10; 45(5):100794.Curr Probl Cancer2021-10-07T00:00:002021Discovery of targeted expression data for novel antibody-based and chimeric antigen receptor-based therapeutics in soft tissue sarcomas using RNA-sequencing: clinical implications.Authorship 103256813Authorship 10326167Authorship 1032618134705134Thein KZ, Piha-Paul SA, Tsimberidou A, Karp DD, Janku F, Zarifa A, Shah J, Milton DR, Bean S, McQuinn L, Gong J, Colen R, Carter BW, Subbiah V, Ogbonna DC, Pant S, Meric-Bernstam F, Naing AInvestigational new drugsCorrection to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study. Invest New Drugs. 2022 Apr; 40(2):461.Invest New Drugs2022-04-01T00:00:002022Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study.34706830Kairemo K, Roszik J, Anderson P, Ravizzini G, Rao A, Macapinlac HA, Subbiah VCurrent problems in cancer18F-sodium fluoride positron emission tomography (NaF-18-PET/CT) radiomic signatures to evaluate responses to alpha-particle Radium-223 dichloride therapy in osteosarcoma metastases. Curr Probl Cancer. 2021 10; 45(5):100797.Curr Probl Cancer2021-10-03T00:00:00202118F-sodium fluoride positron emission tomography (NaF-18-PET/CT) radiomic signatures to evaluate responses to alpha-particle Radium-223 dichloride therapy in osteosarcoma metastases.34706831Subbiah VCurrent problems in cancerOptimizing anti-body drug conjugates and radiopharmaceuticals for precision therapy: The next frontier in precision oncology. Curr Probl Cancer. 2021 10; 45(5):100799.Curr Probl Cancer2021-10-20T00:00:002021Optimizing anti-body drug conjugates and radiopharmaceuticals for precision therapy: The next frontier in precision oncology.Authorship 1034011634767024Ramagopalan S, Gupta A, Arora P, Thorlund K, Ray J, Subbiah VJAMA network openComparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer. JAMA Netw Open. 2021 11 01; 4(11):e2134299.JAMA Netw Open2021-11-01T00:00:002021Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer.Authorship 103479324Authorship 1034862234838156Wen PY, Stein A, van den Bent M, De Greve J, Wick A, de Vos FYFL, von Bubnoff N, van Linde ME, Lai A, Prager GW, Campone M, Fasolo A, Lopez-Martin JA, Kim TM, Mason WP, Hofheinz RD, Blay JY, Cho DC, Gazzah A, Pouessel D, Yachnin J, Boran A, Burgess P, Ilankumaran P, Gasal E, Subbiah VThe Lancet. OncologyDabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. Lancet Oncol. 2022 01; 23(1):53-64.Lancet Oncol2021-11-24T00:00:002021Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial.34853384Coleman N, Subbiah V, Pant S, Patel K, Roy-Chowdhuri S, Yedururi S, Johnson A, Yap TA, Rodon J, Shaw K, Meric-Bernstam FNPJ precision oncologyEmergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition. NPJ Precis Oncol. 2021 Dec 01; 5(1):99.NPJ Precis Oncol2021-12-01T00:00:002021Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition.Authorship 1035160234887213Pestana RC, Beal JR, Parkes A, Hamerschlak N, Subbiah VTrends in cancerImpact of tissue-agnostic approvals for patients with sarcoma. Trends Cancer. 2022 02; 8(2):135-144.Trends Cancer2021-12-06T00:00:002021Impact of tissue-agnostic approvals for patients with sarcoma.Authorship 10362527Authorship 1036407434973234Popat S, Ramagopalan SV, Ray J, Roze S, Subbiah VThe Lancet. OncologyAssessment of tumour-agnostic therapies in basket trials. Lancet Oncol. 2022 01; 23(1):e7.Lancet Oncol2022-01-01T00:00:002022Assessment of tumour-agnostic therapies in basket trials.34965890Thein KZ, Piha-Paul SA, Tsimberidou A, Karp DD, Janku F, Fu S, Subbiah V, Hong DS, Yap TA, Shah J, Milton DR, McQuinn L, Gong J, Tran Y, Carter BW, Colen R, Meric-Bernstam F, Naing AExperimental hematology & oncologySelinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors. Exp Hematol Oncol. 2021 Dec 29; 10(1):59.Exp Hematol Oncol2021-12-29T00:00:002021Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors.Authorship 1037234135018215Subbiah V, Kurzrock ROncotargetUnravelling the underpinnings of hyperprogression and immunotherapy: back to the bench. Oncotarget. 2022; 13:13-15.Oncotarget2022-01-05T00:00:002022Unravelling the underpinnings of hyperprogression and immunotherapy: back to the bench.Authorship 10391837Authorship 10393991Authorship 10395348Authorship 10395403Authorship 103960915Authorship 103961713Authorship 10406801Authorship 1041396435130943Voon PJ, Chen EX, Chen HX, Lockhart AC, Sahebjam S, Kelly K, Vaishampayan UN, Subbiah V, Razak AR, Renouf DJ, Hotte SJ, Singh A, Bedard PL, Hansen AR, Ivy SP, Wang L, Stayner LA, Siu LL, Spreafico AJournal of experimental & clinical cancer research : CRPhase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction. J Exp Clin Cancer Res. 2022 Feb 07; 41(1):51.J Exp Clin Cancer Res2022-02-07T00:00:002022Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction.35131875Duca M, Lim DW, Subbiah V, Takahashi S, Sarantopoulos J, Varga A, D'Alessio JA, Abrams T, Sheng Q, Tan EY, Rosa MS, Gonzalez-Maffe J, Sand-Dejmek J, Fabre C, Martin MMolecular cancer therapeuticsA First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors. Mol Cancer Ther. 2022 04 01; 21(4):625-634.Mol Cancer Ther2022-04-01T00:00:002022A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors.35135123Haraldsdottir S, Janku F, Poi M, Timmers C, Geyer S, Schaaf LJ, Sexton J, Wei L, Thurmond J, Velez-Bravo V, Stepanek VM, Bertino EM, Kendra K, Mortazavi A, Subbiah V, Phelps M, Shah MHJCO precision oncologyPhase I Trial of Dabrafenib and Pazopanib in BRAF Mutated Advanced Malignancies. JCO Precis Oncol. 2018 Nov; 2:1-19.JCO Precis Oncol2018-11-01T00:00:002018Phase I Trial of Dabrafenib and Pazopanib in BRAF Mutated Advanced Malignancies.35135166Iyer PC, Cote GJ, Hai T, Gule-Monroe M, Bui-Griffith J, Williams MD, Hess K, Hofmann MC, Dadu R, Zafereo M, Busaidy NL, Ferrarotto R, Subbiah V, Gross N, Gunn BG, Skinner HD, Garden AS, Cabanillas MEJCO precision oncologyCirculating BRAF V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma. JCO Precis Oncol. 2018 Nov; 2:1-11.JCO Precis Oncol2018-11-01T00:00:002018Circulating BRAF V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma.35121874Subbiah VNature cancerA global effort to understand the riddles of COVID-19 and cancer. Nat Cancer. 2020 10; 1(10):943-945.Nat Cancer2020-10-01T00:00:002020A global effort to understand the riddles of COVID-19 and cancer.35100715Peguero J, Sohal DPS, O'Neil BH, Safran H, Kelly K, Grilley-Olson JE, Subbiah V, Nadauld L, Purkayastha D, Stealey E, Ricart AD, Kang BP, Eder JPJCO precision oncologyTissue/Site-Agnostic Study of Ribociclib for Tumors With Cyclin D-CDK4/6 Pathway Genomic Alterations: A Phase II, Open-Label, Single-Arm Basket Study. JCO Precis Oncol. 2019 Dec; 3:1-10.JCO Precis Oncol2019-12-01T00:00:002019Tissue/Site-Agnostic Study of Ribociclib for Tumors With Cyclin D-CDK4/6 Pathway Genomic Alterations: A Phase II, Open-Label, Single-Arm Basket Study.35176457Subbiah V, Iannotti NO, Gutierrez M, Smith DC, F?liz L, Lihou CF, Tian C, Silverman IM, Ji T, Saleh MAnnals of oncology : official journal of the European Society for Medical OncologyFIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies. Ann Oncol. 2022 05; 33(5):522-533.Ann Oncol2022-02-14T00:00:002022FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.35240095Wen PY, Burgess P, Ilankumaran P, Subbiah VThe Lancet. OncologyROAR trial: which treatment is effective after progression? - Authors' reply. Lancet Oncol. 2022 03; 23(3):e94.Lancet Oncol2022-03-01T00:00:002022ROAR trial: which treatment is effective after progression? - Authors' reply.Authorship 10433122Authorship 10437756Authorship 1044706135413124Adashek JJ, Menta AK, Reddy NK, Desai AP, Roszik J, Subbiah VMolecular cancer therapeuticsTissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors. Mol Cancer Ther. 2022 06 01; 21(6):871-878.Mol Cancer Ther2022-06-01T00:00:002022Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors.35486638Subbiah V, Bra?a I, Longhi A, Boni V, Delord JP, Awada A, Boudou-Rouquette P, Sarantopoulos J, Shapiro GI, Elias A, Ratan R, Fernandez C, Kahatt C, Cullell-Young M, Siguero M, Zeaiter A, Chawla SPClinical cancer research : an official journal of the American Association for Cancer ResearchAntitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study. Clin Cancer Res. 2022 07 01; 28(13):2762-2770.Clin Cancer Res2022-07-01T00:00:002022Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study.35373284Moyers JT, Subbiah VCancer discoveryThink Globally, Act Locally: Globalizing Precision Oncology. Cancer Discov. 2022 04 01; 12(4):886-888.Cancer Discov2022-04-01T00:00:002022Think Globally, Act Locally: Globalizing Precision Oncology.Authorship 1045093435507888Capone S, Ketonen L, Weathers SP, Subbiah VJCO precision oncologyActivity of Pemigatinib in Pilocytic Astrocytoma and FGFR1N546K Mutation. JCO Precis Oncol. 2022 04; 6:e2100371.JCO Precis Oncol2022-04-01T00:00:002022Activity of Pemigatinib in Pilocytic Astrocytoma and FGFR1N546K Mutation.Authorship 10465389Authorship 1046564835610322Yao S, Meric-Bernstam F, Hong D, Janku F, Naing A, Piha-Paul SA, Tsimberidou AM, Karp D, Subbiah V, Yap TA, Ahnert JR, Pant S, Dumbrava EEI, Wathoo C, Campbell E, Yu L, Yamamura Y, Fu SScientific reportsClinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences. Sci Rep. 2022 05 24; 12(1):8701.Sci Rep2022-05-24T00:00:002022Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences.35612853Popat S, Liu SV, Scheuer N, Gupta A, Hsu GG, Ramagopalan SV, Griesinger F, Subbiah VJAMA network openAssociation Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non-Small Cell Lung Cancer. JAMA Netw Open. 2022 05 02; 5(5):e2214046.JAMA Netw Open2022-05-02T00:00:002022Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non-Small Cell Lung Cancer.Authorship 10476132Authorship 10476416Authorship 1047656135663538Desai A, Subbiah VJournal of immunotherapy and precision oncologyCOVID-19 Pandemic and Cancer Clinical Trial Pandemonium: Finding the Silver Lining. J Immunother Precis Oncol. 2021 May; 4(2):64-66.J Immunother Precis Oncol2020-11-16T00:00:002020COVID-19 Pandemic and Cancer Clinical Trial Pandemonium: Finding the Silver Lining.35663835DiPeri TP, Demirhan M, Karp DD, Fu S, Hong DS, Subbiah V, Lim J, Ballester LY, Tayar JH, Suarez-Almazor ME, Javle M, Meric-Bernstam FJournal of immunotherapy and precision oncologyCorticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma. J Immunother Precis Oncol. 2022 Feb; 5(1):26-30.J Immunother Precis Oncol2022-02-04T00:00:002022Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma.35665021Subbiah VJournal of immunotherapy and precision oncologyTissue is Still the Issue for Precision Oncology: A Novel Web-Based Platform for Lesion Selection and Biopsy Specimen Acquisition. J Immunother Precis Oncol. 2021 Nov; 4(4):176-177.J Immunother Precis Oncol2021-07-08T00:00:002021Tissue is Still the Issue for Precision Oncology: A Novel Web-Based Platform for Lesion Selection and Biopsy Specimen Acquisition.Authorship 1048199835715405Popat S, Liu SV, Scheuer N, Hsu GG, Lockhart A, Ramagopalan SV, Griesinger F, Subbiah VNature communicationsAddressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer. Nat Commun. 2022 06 17; 13(1):3500.Nat Commun2022-06-17T00:00:002022Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer.Authorship 1048903135727698Subbiah V, Gan BClinical cancer research : an official journal of the American Association for Cancer ResearchTargeting Ferroptosis Vulnerability in Synovial Sarcoma: Is It All About ME1? Clin Cancer Res. 2022 08 15; 28(16):3408-3410.Clin Cancer Res2022-08-15T00:00:002022Targeting Ferroptosis Vulnerability in Synovial Sarcoma: Is It All About ME1?Authorship 1049323335775194Atrafi F, Boix O, Subbiah V, Diamond JR, Chawla SP, Tolcher AW, LoRusso PM, Eder JP, Gutierrez M, Sankhala K, Rajagopalan P, Genvresse I, Langer S, Mathijssen RHJ, Verweij J, Bruns I, Lolkema MPClinical cancer research : an official journal of the American Association for Cancer ResearchCorrection: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation. Clin Cancer Res. 2022 Jul 01; 28(13):2969.Clin Cancer Res2022-07-01T00:00:002022Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation.Authorship 1049917935791692Morgan G, Agarwal N, Choueiri TK, Dizon DS, Hamilton EP, Markham MJ, Lewis M, Prowell TM, Rugo HS, Subbiah V, West HLCancer discoveryThe (R)evolution of Social Media in Oncology: Engage, Enlighten, and Encourage. Cancer Discov. 2022 07 06; 12(7):1620-1624.Cancer Discov2022-07-06T00:00:002022The (R)evolution of Social Media in Oncology: Engage, Enlighten, and Encourage.Authorship 1050304835834760Gouda MA, Huang HJ, Piha-Paul SA, Call SG, Karp DD, Fu S, Naing A, Subbiah V, Pant S, Dustin DJ, Tsimberidou AM, Hong DS, Rodon J, Meric-Bernstam F, Janku FJCO precision oncologyLongitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers. JCO Precis Oncol. 2022 07; 6:e2100512.JCO Precis Oncol2022-07-01T00:00:002022Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers.Authorship 1050565935830841Longo-Mu?oz F, Castellano D, Alexandre J, Chawla SP, Fern?ndez C, Kahatt C, Alfaro V, Siguero M, Zeaiter A, Moreno V, Sanz-Garc?a E, Awada A, Santaballa A, Subbiah VEuropean journal of cancer (Oxford, England : 1990)Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study. Eur J Cancer. 2022 09; 172:340-348.Eur J Cancer2022-07-10T00:00:002022Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study.Authorship 10615382Authorship 10603372Authorship 10586516Authorship 105614617Authorship 10543844Authorship 10558691Authorship 106140812Authorship 105901721Authorship 10610238Authorship 10571942Authorship 106025618Authorship 10620176Authorship 10588802Authorship 10552652Authorship 10561501Authorship 10555056Authorship 105474915Authorship 105463734Authorship 105976017Authorship 10570272Authorship 10559931Authorship 10578287Authorship 105551519Authorship 105490323Authorship 10588582Authorship 10588812Authorship 106079614Authorship 1056949136383913Gouda MA, Subbiah VCancer journal (Sudbury, Mass.)Strategies for Mitigating Antibody-Drug Conjugate Related Adverse Events for Precision Therapy. Cancer J. 2022 Nov-Dec 01; 28(6):496-507.Cancer J2022-11-01T00:00:002022Strategies for Mitigating Antibody-Drug Conjugate Related Adverse Events for Precision Therapy.36284306Parikh K, Banna G, Liu SV, Friedlaender A, Desai A, Subbiah V, Addeo AJournal of hematology & oncologyDrugging KRAS: current perspectives and state-of-art review. J Hematol Oncol. 2022 10 25; 15(1):152.J Hematol Oncol2022-10-25T00:00:002022Drugging KRAS: current perspectives and state-of-art review.36288393Moyers JT, Pestana RC, Roszik J, Hong DS, Naing A, Fu S, Piha-Paul S, Yap TA, Karp D, Rodon J, Livingston A, Zarzour MA, Ravi V, Patel S, Benjamin RS, Ludwig J, Herzog C, Ratan R, Somaiah N, Conley A, Gorlick R, Meric-Bernstam F, Subbiah VClinical cancer research : an official journal of the American Association for Cancer ResearchExamining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102). Clin Cancer Res. 2023 01 17; 29(2):401-409.Clin Cancer Res2023-01-17T00:00:002023Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102).36031605Persha HE, Kato S, De P, Adashek JJ, Sicklick JK, Subbiah V, Kurzrock RJournal of hematology & oncologyOsteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response. J Hematol Oncol. 2022 08 28; 15(1):119.J Hematol Oncol2022-08-28T00:00:002022Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response.36383911Prakash R, Subbiah V, Iyer SPCancer journal (Sudbury, Mass.)Evolving Landscape of Antibody Drug Conjugates in Lymphoma. Cancer J. 2022 Nov-Dec 01; 28(6):479-487.Cancer J2022-11-01T00:00:002022Evolving Landscape of Antibody Drug Conjugates in Lymphoma.35977349Dankner M, Wang Y, Fazelzad R, Johnson B, Nebhan CA, Dagogo-Jack I, Myall NJ, Richtig G, Bracht JWP, Gerlinger M, Shinozaki E, Yoshino T, Kotani D, Fangusaro JR, Gautschi O, Mazieres J, Sosman JA, Kopetz S, Subbiah V, Davies MA, Groover AL, Sullivan RJ, Flaherty KT, Johnson DB, Benedetti A, Cescon DW, Spreafico A, Zogopoulos G, Rose AANJCO precision oncologyClinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors. JCO Precis Oncol. 2022 08; 6:e2200107.JCO Precis Oncol2022-08-01T00:00:002022Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors.35917516Babiker H, Borazanci E, Subbiah V, Agarwala S, Algazi A, Schachter J, Lotem M, Maurice-Dror C, Hendler D, Rahimian S, Minderman H, Haymaker C, Mahadevan D, Bernatchez C, Murthy R, Hultsch R, Kaplan N, Woodhead G, Hennemeyer C, Chunduru S, Anderson PM, Diab A, Puzanov IClinical cancer research : an official journal of the American Association for Cancer ResearchTilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101). Clin Cancer Res. 2022 12 01; 28(23):5079-5087.Clin Cancer Res2022-12-01T00:00:002022Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101).36192554Subbiah V, Wirth LJ, Kurzrock R, Pazdur R, Beaver JA, Singh H, Mehta GUNature medicineAccelerated approvals hit the target in precision oncology. Nat Med. 2022 10; 28(10):1976-1979.Nat Med2022-10-01T00:00:002022Accelerated approvals hit the target in precision oncology.36370692Gouda MA, Subbiah VMed (New York, N.Y.)Exportin(g) precision oncology beyond genomics with XPO1 inhibition. Med. 2022 11 11; 3(11):730-732.Med2022-11-11T00:00:002022Exportin(g) precision oncology beyond genomics with XPO1 inhibition.36302890Vo HH, Fu S, Hong DS, Karp DD, Piha-Paul S, Subbiah V, Janku F, Naing A, Yap TA, Rodon J, Ajani JA, Cartwright C, Johnson A, Song IW, Beck J, Kahle M, Nogueras-Gonzalez GM, Miller V, Chao C, Vining DJ, Berry DA, Meric-Bernstam F, Tsimberidou AMNPJ precision oncologyChallenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology. NPJ Precis Oncol. 2022 Oct 27; 6(1):78.NPJ Precis Oncol2022-10-27T00:00:002022Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology.36122315Drilon A, Subbiah V, Gautschi O, Tomasini P, de Braud F, Solomon BJ, Shao-Weng Tan D, Alonso G, Wolf J, Park K, Goto K, Soldatenkova V, Szymczak S, Barker SS, Puri T, Bence Lin A, Loong H, Besse BJournal of clinical oncology : official journal of the American Society of Clinical OncologySelpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial. J Clin Oncol. 2023 01 10; 41(2):385-394.J Clin Oncol2022-09-19T00:00:002022Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial.36199491Barber FD, Campbell E, Yamamura Y, Patterson CJ, Hartnett AC, Kinahan H, Miller VA, Brink AL, Poullard A, Urschel GE, Brantley A, Cepeda IG, Goswami P, Charles S, Philip S, Bresser S, Musekiwa-Adjei S, Perez N, Le H, Phillips P, Subbiah V, Meric-Bernstam F, Dumbrava EEJournal of the advanced practitioner in oncologyManagement of Adverse Events in Early Clinical Trials by Advanced Practice Providers in the Outpatient Setting: The University of Texas MD Anderson Cancer Center Experience. J Adv Pract Oncol. 2022 Sep; 13(7):664-672.J Adv Pract Oncol2022-10-12T00:00:002022Management of Adverse Events in Early Clinical Trials by Advanced Practice Providers in the Outpatient Setting: The University of Texas MD Anderson Cancer Center Experience.36503246Contrera KJ, Gule-Monroe MK, Hu MI, Cabanillas ME, Busaidy NL, Dadu R, Waguespack SG, Wang JR, Maniakas A, Lai SY, Diersing J, Kwon M, Grubbs EG, Subbiah V, Williams MD, Zafereo METhyroid : official journal of the American Thyroid AssociationNeoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series. Thyroid. 2023 01; 33(1):129-132.Thyroid2023-01-01T00:00:002023Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series.36457575Anderson PM, Subbiah V, Trucco MMFrontiers in medicineCurrent and future targeted alpha particle therapies for osteosarcoma: Radium-223, actinium-225, and thorium-227. Front Med (Lausanne). 2022; 9:1030094.Front Med (Lausanne)2022-11-15T00:00:002022Current and future targeted alpha particle therapies for osteosarcoma: Radium-223, actinium-225, and thorium-227.36411943Nelson BE, Adashek JJ, Lin SH, Subbiah VCancer medicineOn target methods to induce abscopal phenomenon for Off-Target effects: From happenstance to happenings. Cancer Med. 2023 03; 12(6):6451-6465.Cancer Med2022-11-21T00:00:002022On target methods to induce abscopal phenomenon for Off-Target effects: From happenstance to happenings.36646803Subbiah VNature medicineThe next generation of evidence-based medicine. Nat Med. 2023 01; 29(1):49-58.Nat Med2023-01-16T00:00:002023The next generation of evidence-based medicine.35962206Subbiah V, Cassier PA, Siena S, Garralda E, Paz-Ares L, Garrido P, Nadal E, Vuky J, Lopes G, Kalemkerian GP, Bowles DW, Seetharam M, Chang J, Zhang H, Green J, Zalutskaya A, Schuler M, Fan Y, Curigliano GNature medicinePan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial. Nat Med. 2022 08; 28(8):1640-1645.Nat Med2022-08-12T00:00:002022Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial.36108341Kreitman RJ, Moreau P, Ravandi F, Hutchings M, Gazzah A, Michallet AS, Wainberg ZA, Stein A, Dietrich S, de Jonge MJA, Willenbacher W, De Gr?ve J, Arons E, Ilankumaran P, Burgess P, Gasal E, Subbiah VBloodDabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia. Blood. 2023 03 02; 141(9):996-1006.Blood2023-03-02T00:00:002023Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia.36108661Subbiah V, Wolf J, Konda B, Kang H, Spira A, Weiss J, Takeda M, Ohe Y, Khan S, Ohashi K, Soldatenkova V, Szymczak S, Sullivan L, Wright J, Drilon AThe Lancet. OncologyTumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol. 2022 10; 23(10):1261-1273.Lancet Oncol2022-09-12T00:00:002022Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.35994695Caglevic C, Rolfo C, Gil-Bazo I, Cardona A, Sapunar J, Hirsch FR, Gandara DR, Morgan G, Novello S, Garassino MC, Mountzios G, Leighl NB, Bretel D, Arrieta O, Addeo A, Liu SV, Corrales L, Subbiah V, Aboitiz F, Villarroel-Espindola F, Reyes-Cosmelli F, Morales R, Mahave M, Raez L, Alatorre J, Santos E, Ubillos L, Tan DSW, Zielinski CJCO global oncologyThe Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent Considerations. JCO Glob Oncol. 2022 08; 8:e2200123.JCO Glob Oncol2022-08-01T00:00:002022The Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent Considerations.36097568Raad I, Hachem R, Masayuki N, Datoguia T, Dagher H, Jiang Y, Subbiah V, Siddiqui B, Bayle A, Somer R, Cruz AF, Gorak E, Bhinder A, Mori N, Hamerschlak N, Shelanski S, Dragivich T, Kiat YEV, Fakhreddine S, Hanna PA, Chemaly RF, Mulanovich V, Adachi J, Borjan J, Khawaja F, Granwehr B, John T, Guevara EY, Torres H, Ammakkanavar NR, Yibirin M, Reyes-Gibby CC, Pande M, Ali N, Rojo RD, Ali SM, Deeba RE, Chaftari P, Matsuo T, Ishikawa K, Hasegawa R, Aguado-Noya R, Garc?a-Garc?a ?, Puchol CT, Lee DG, Slavin M, Teh B, Arias CA, Data-Driven Determinants for COVID-19 Oncology Discovery Effort (D3CODE) Team, Kontoyiannis DP, Malek AE, Chaftari AMmedRxiv : the preprint server for health sciencesInternational Multicenter Study Comparing Cancer to Non-Cancer Patients with COVID-19: Impact of Risk Factors and Treatment Modalities on Survivorship. medRxiv. 2022 Aug 26.medRxiv2022-08-26T00:00:002022International Multicenter Study Comparing Cancer to Non-Cancer Patients with COVID-19: Impact of Risk Factors and Treatment Modalities on Survivorship.36632846Addeo A, Miranda-Morales E, den Hollander P, Friedlaender A, O Sintim H, Wu J, Mani SA, Subbiah VPharmacology & therapeuticsRET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives. Pharmacol Ther. 2023 02; 242:108344.Pharmacol Ther2023-01-09T00:00:002023RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives.36309827Desai A, Subbiah VCancerRationalizing rules for immunotherapy combination trials: About time for precision immunotherapy. Cancer. 2023 01 01; 129(1):11-14.Cancer2022-10-30T00:00:002022Rationalizing rules for immunotherapy combination trials: About time for precision immunotherapy.36326765Ramagopalan SV, Popat S, Gupta A, Boyne DJ, Lockhart A, Hsu G, O'Sullivan DE, Inskip J, Ray J, Cheung WY, Griesinger F, Subbiah VJAMA network openTransportability of Overall Survival Estimates From US to Canadian Patients With Advanced Non-Small Cell Lung Cancer With Implications for Regulatory and Health Technology Assessment. JAMA Netw Open. 2022 11 01; 5(11):e2239874.JAMA Netw Open2022-11-01T00:00:002022Transportability of Overall Survival Estimates From US to Canadian Patients With Advanced Non-Small Cell Lung Cancer With Implications for Regulatory and Health Technology Assessment.36658425Yap TA, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, Kantarjian HM, Ravandi F, Collins ME, Francesco MED, Dumbrava EE, Fu S, Gao S, Gay JP, Gera S, Han J, Hong DS, Jabbour EJ, Ju Z, Karp DD, Lodi A, Molina JR, Baran N, Naing A, Ohanian M, Pant S, Pemmaraju N, Bose P, Piha-Paul SA, Rodon J, Salguero C, Sasaki K, Singh AK, Subbiah V, Tsimberidou AM, Xu QA, Yilmaz M, Zhang Q, Li Y, Bristow CA, Bhattacharjee MB, Tiziani S, Heffernan TP, Vellano CP, Jones P, Heijnen CJ, Kavelaars A, Marszalek JR, Konopleva MNature medicineComplex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med. 2023 01; 29(1):115-126.Nat Med2023-01-19T00:00:002023Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials.35999229Mendoza TR, Hong DS, Peterson CB, Stephen B, Dumbrava E, Pant S, Tsimberidou AM, Yap TA, Sheshadri A, Altan M, George G, Castillo L, Rodriguez E, Gong J, Subbiah V, Janku F, Fu S, Piha-Paul SA, Ahnert JR, Karp DD, Cleeland C, Meric-Bernstam F, Naing AScientific reportsPatient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial. Sci Rep. 2022 08 23; 12(1):14367.Sci Rep2022-08-23T00:00:002022Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial.36494311Bhamidipati D, Subbiah VTrends in cancerImpact of tissue-agnostic approvals for patients with gastrointestinal malignancies. Trends Cancer. 2023 03; 9(3):237-249.Trends Cancer2022-12-07T00:00:002022Impact of tissue-agnostic approvals for patients with gastrointestinal malignancies.36077869Wagner MJ, Hennessy C, Beeghly A, French B, Shah DP, Croessmann S, Vilar-Compte D, Ruiz-Garcia E, Ingham M, Schwartz GK, Painter CA, Chugh R, Fecher L, Park C, Zamulko O, Trent JC, Subbiah V, Khaki AR, Tachiki L, Nakasone ES, Loggers ET, Labaki C, Saliby RM, McKay RR, Ajmera A, Griffiths EA, Puzanov I, Tap WD, Hwang C, Tejwani S, Jhawar SR, Hayes-Lattin B, Wulff-Burchfield E, Kasi A, Reuben DY, Nagaraj G, Joshi M, Polimera H, Kulkarni AA, Esfahani K, Kwon DH, Paoluzzi L, Bilen MA, Durbin EB, Grivas P, Warner JL, Davis EJ, COVID-19 and Cancer ConsortiumCancersDemographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study. Cancers (Basel). 2022 Sep 05; 14(17).Cancers (Basel)2022-09-05T00:00:002022Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study.Authorship 106335811Authorship 10631071336725142Casolino R, Johns AL, Courtot M, Lawlor RT, De Lorenzo F, Horgan D, Mateo J, Normanno N, Rubin M, Stein L, Subbiah V, Westphalen BC, Lawler M, Park K, Perdomo S, Yoshino T, Wu J, Biankin AV, Lancet Oncology Commission on Cancer Omics and Precision OncologyThe Lancet. OncologyAccelerating cancer omics and precision oncology in health care and research: a Lancet Oncology Commission. Lancet Oncol. 2023 02; 24(2):123-125.Lancet Oncol2023-02-01T00:00:002023Accelerating cancer omics and precision oncology in health care and research: a Lancet Oncology Commission.36715684Raad II, Hachem R, Masayuki N, Datoguia T, Dagher H, Jiang Y, Subbiah V, Siddiqui B, Bayle A, Somer R, Fern?ndez Cruz A, Gorak E, Bhinder A, Mori N, Hamerschlak N, Shelanski S, Dragovich T, Vong Kiat YE, Fakhreddine S, Pierre AH, Chemaly RF, Mulanovich V, Adachi J, Borjan J, Khawaja F, Granwehr B, John T, Yepez EY, Torres HA, Ammakkanavar NR, Yibirin M, Reyes-Gibby CC, Pande M, Ali N, Rojo RD, Ali SM, Deeba RE, Chaftari P, Matsuo T, Ishikawa K, Hasegawa R, Aguado-Noya R, Garc?a AG, Puchol CT, Lee DG, Slavin M, Teh B, Arias CA, Data-Driven Determinants for COVID-19 Oncology Discovery Effort (D3CODE) Team, Kontoyiannis DP, Malek AE, Chaftari AMeLifeInternational multicenter study comparing COVID-19 in patients with cancer to patients without cancer: Impact of risk factors and treatment modalities on survivorship. Elife. 2023 01 30; 12.Elife2023-01-30T00:00:002023International multicenter study comparing COVID-19 in patients with cancer to patients without cancer: Impact of risk factors and treatment modalities on survivorship.Authorship 106360520Authorship 10637671136762947Zhao X, Wang JR, Dadu R, Busaidy NL, Xu L, Learned KO, Chasen NN, Vu T, Maniakas A, Eguia AA, Diersing J, Gross ND, Goepfert R, Lai SY, Hofmann MC, Ferrarotto R, Lu C, Gunn GB, Spiotto MT, Subbiah V, Williams MD, Cabanillas ME, Zafereo METhyroid : official journal of the American Thyroid AssociationSurgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAFV600E Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Study. Thyroid. 2023 04; 33(4):484-491.Thyroid2023-03-20T00:00:002023Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAFV600E Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Study.36751659Son J, Lin HY, Fu S, Biter AB, Dumbrava EE, Karp DD, Naing A, Pant S, Piha-Paul SA, Rodon J, Subbiah V, Tsimberidou AM, Yap TA, Frumovitz MM, Jazaeri AA, Ramirez PT, Westin SN, Yuan Y, Meric-Bernstam F, Hong DSJournal of immunotherapy and precision oncologyPredictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer. J Immunother Precis Oncol. 2023 Feb; 6(1):10-18.J Immunother Precis Oncol2023-01-06T00:00:002023Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer.Authorship 10644531636801912Nelson BE, Roszik J, Janku F, Hong DS, Kato S, Naing A, Piha-Paul S, Fu S, Tsimberidou A, Cabanillas M, Busaidy NL, Javle M, Byers LA, Heymach JV, Meric-Bernstam F, Subbiah VNPJ precision oncologyBRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study. NPJ Precis Oncol. 2023 Feb 18; 7(1):19.NPJ Precis Oncol2023-02-18T00:00:002023BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study.Authorship 10652356Authorship 1065284436893753Nelson BE, Adashek JJ, Lin SH, Subbiah VMed (New York, N.Y.)The abscopal effect in patients with cancer receiving immunotherapy. Med. 2023 04 14; 4(4):233-244.Med2023-03-08T00:00:002023The abscopal effect in patients with cancer receiving immunotherapy.36882377Janku F, Javle MM, Sen S, Pant S, Bramwell LG, Subbiah V, Way T, Wages DS, Wheeler CA, Suzuki T, Saeki K, Subach RA, Madden T, Maier G, Johansen MJ, Cheung K, Falchook GSCancerA phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF-10502-01 for the treatment of advanced solid tumors. Cancer. 2023 05 15; 129(10):1537-1546.Cancer2023-03-07T00:00:002023A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF-10502-01 for the treatment of advanced solid tumors.Authorship 10658341Authorship 1065913536914722Belli C, Repetto M, Anand S, Porta C, Subbiah V, Curigliano GBritish journal of cancerThe emerging role of PI3K inhibitors for solid tumour treatment and beyond. Br J Cancer. 2023 06; 128(12):2150-2162.Br J Cancer2023-03-13T00:00:002023The emerging role of PI3K inhibitors for solid tumour treatment and beyond.36930859Subbiah V, Kurzrock RJournal of clinical oncology : official journal of the American Society of Clinical OncologyUniversal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: Genomics Is the Diagnosis. J Clin Oncol. 2023 06 10; 41(17):3100-3103.J Clin Oncol2023-03-17T00:00:002023Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: Genomics Is the Diagnosis.Authorship 1066058336946766Desai A, Reddy NK, Subbiah VCancerTop advances of the year: Precision oncology. Cancer. 2023 06 01; 129(11):1634-1642.Cancer2023-03-22T00:00:002023Top advances of the year: Precision oncology.Authorship 1067308137059834Subbiah V, Kreitman RJ, Wainberg ZA, Gazzah A, Lassen U, Stein A, Wen PY, Dietrich S, de Jonge MJA, Blay JY, Italiano A, Yonemori K, Cho DC, de Vos FYFL, Moreau P, Fernandez EE, Schellens JHM, Zielinski CC, Redhu S, Boran A, Passos VQ, Ilankumaran P, Bang YJNature medicineDabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. Nat Med. 2023 05; 29(5):1103-1112.Nat Med2023-04-14T00:00:002023Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial.Authorship 10683472Authorship 106845321Authorship 106764934Authorship 106805311Authorship 10689305Authorship 10683042Authorship 10682625Authorship 10677891337119430Surana R, Gonzalez GN, Rogers J, Hong DS, Yap TA, Rodon J, Naing A, Wolff RA, Smaglo BG, Bernstam FM, Subbiah V, Pant SJournal of gastrointestinal cancerUtility of Established Prognostic Scoring Systems for Patients with Advanced Pancreatic Adenocarcinoma Enrolled in Immunotherapy-Based Early-Phase Clinical Trials. J Gastrointest Cancer. 2023 Dec; 54(4):1308-1315.J Gastrointest Cancer2023-04-29T00:00:002023Utility of Established Prognostic Scoring Systems for Patients with Advanced Pancreatic Adenocarcinoma Enrolled in Immunotherapy-Based Early-Phase Clinical Trials.37072571Alhalabi O, Groisberg R, Zinner R, Hahn AW, Naing A, Zhang S, Tsimberidou AM, Rodon J, Fu S, Yap TA, Hong DS, Sun M, Jiang Y, Pant S, Shah AY, Zurita A, Tannir NM, Vikram R, Roszik J, Meric-Bernstam F, Subbiah VNPJ precision oncologyPhase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies. NPJ Precis Oncol. 2023 Apr 18; 7(1):37.NPJ Precis Oncol2023-04-18T00:00:002023Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies.37058010Carmagnani Pestana R, Moyers JT, Roszik J, Sen S, Hong DS, Naing A, Herzog CE, Fu S, Piha-Paul SA, Rodon J, Yap TA, Karp DD, Tsimberidou AM, Pant S, Zarzour MA, Ratan R, Ravi V, Benjamin RS, Lazar AJ, Wang WL, Daw N, Gill JB, Harrison DJ, Lewis VO, Roland CL, Patel SR, Livingston JA, Somaiah N, Ludwig JA, Conley AP, Hamerschlak N, Gorlick R, Meric-Bernstam F, Subbiah VClinical cancer research : an official journal of the American Association for Cancer ResearchImpact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101). Clin Cancer Res. 2023 05 01; 29(9):1708-1718.Clin Cancer Res2023-05-01T00:00:002023Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101).37061987Gouda MA, Nelson BE, Buschhorn L, Wahida A, Subbiah VClinical cancer research : an official journal of the American Association for Cancer ResearchTumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications. Clin Cancer Res. 2023 08 01; 29(15):2753-2760.Clin Cancer Res2023-08-01T00:00:002023Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications.37036891Horgan D, Capoluongo E, Dube F, Trapani D, Malapelle U, Rovite V, Omar MI, Alix-Panabi?res C, Rutkowski P, Bayle A, Hackshaw A, Hofman P, Subbiah VDiagnosis (Berlin, Germany)Clouds across the new dawn for clinical, diagnostic and biological data: accelerating the development, delivery and uptake of personalized medicine. Diagnosis (Berl). 2023 Nov 01; 10(4):356-362.Diagnosis (Berl)2023-04-10T00:00:002023Clouds across the new dawn for clinical, diagnostic and biological data: accelerating the development, delivery and uptake of personalized medicine.37070849Gouda MA, Buschhorn L, Schneeweiss A, Wahida A, Subbiah VCancer discoveryN-of-1 Trials in Cancer Drug Development. Cancer Discov. 2023 06 02; 13(6):1301-1309.Cancer Discov2023-06-02T00:00:002023N-of-1 Trials in Cancer Drug Development.37011025Morgan G, Subbiah VCancerRare disease research powered by empowered patients: solving the zebra puzzle through social media. Cancer. 2023 07 15; 129(14):2128-2131.Cancer2023-04-03T00:00:002023Rare disease research powered by empowered patients: solving the zebra puzzle through social media.37125861Desai A, Subbiah VClinical cancer research : an official journal of the American Association for Cancer ResearchDirect-to-Patient Clinical Trials: One Small Step or a Giant Leap? Clin Cancer Res. 2023 07 05; 29(13):2339-2341.Clin Cancer Res2023-07-05T00:00:002023Direct-to-Patient Clinical Trials: One Small Step or a Giant Leap?Authorship 1070772237159870Gouda MA, Subbiah VAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual MeetingExpanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E-Positive Adult and Pediatric Solid Tumors. Am Soc Clin Oncol Educ Book. 2023 May; 43:e404770.Am Soc Clin Oncol Educ Book2023-05-01T00:00:002023Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E-Positive Adult and Pediatric Solid Tumors.Authorship 10728326Authorship 10721452Authorship 10740873Authorship 10727101Authorship 10727421Authorship 10737061Authorship 10742991Authorship 10726165Authorship 10739036Authorship 10722454Authorship 10737922Authorship 1073556837311055Nelson BE, Tsimberidou AM, Fu X, Fu S, Subbiah V, Sood AK, Rodon J, Karp DD, Blumenschein G, Kopetz S, Pant S, Piha-Paul SAThe oncologistA Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors. Oncologist. 2023 Dec 11; 28(12):1100-e1292.Oncologist2023-12-11T00:00:002023A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors.37314501Piha-Paul SA, Tseng C, Tran HT, Gao M, Karp DD, Subbiah V, Tsimberidou AM, Kawedia JD, Fu S, Pant S, Yap TA, Morris VK, Kee BK, Blum Murphy M, Lim J, Meric-Bernstam FCancer chemotherapy and pharmacologyA phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation. Cancer Chemother Pharmacol. 2023 08; 92(2):107-118.Cancer Chemother Pharmacol2023-06-14T00:00:002023A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation.37311150Subbiah V, Kurzrock RJournal of clinical oncology : official journal of the American Society of Clinical OncologyReply to S. Sorscher. J Clin Oncol. 2023 Aug 20; 41(24):4058-4059.J Clin Oncol2023-06-13T00:00:002023Reply to S. Sorscher.37360768Gouda MA, Subbiah VTherapeutic advances in medical oncologyPrecision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers. Ther Adv Med Oncol. 2023; 15:17588359231177015.Ther Adv Med Oncol2023-06-21T00:00:002023Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers.37407364Blum J, Menta AK, Zhao X, Yang VB, Gouda MA, Subbiah VTrends in cancerPearls and pitfalls of ChatGPT in medical oncology. Trends Cancer. 2023 10; 9(10):788-790.Trends Cancer2023-07-04T00:00:002023Pearls and pitfalls of ChatGPT in medical oncology.37324544Bhamidipati D, Subbiah VOncoscienceLurbinectedin, a DNA minor groove inhibitor for neuroendocrine neoplasms beyond small cell lung cancer. Oncoscience. 2023; 10:22-23.Oncoscience2023-06-14T00:00:002023Lurbinectedin, a DNA minor groove inhibitor for neuroendocrine neoplasms beyond small cell lung cancer.37277734Lazure P, Sireci A, Subbiah V, Murray S, Groh? C, Sherman SI, Kelly E, Bubach P, P?loquin SBMC medical educationChallenges in diagnosis and biomarker testing for RET-altered lung and thyroid cancer care: an international mixed-method study. BMC Med Educ. 2023 Jun 05; 23(1):410.BMC Med Educ2023-06-05T00:00:002023Challenges in diagnosis and biomarker testing for RET-altered lung and thyroid cancer care: an international mixed-method study.37259805Nelson BE, Adashek JJ, Sheth AA, Subbiah VMolecular cancer therapeuticsPredicting the Abscopal Effect: Associated Tumor Histologic Subtypes and Biomarkers. Mol Cancer Ther. 2023 06 01; 22(6):706-716.Mol Cancer Ther2023-06-01T00:00:002023Predicting the Abscopal Effect: Associated Tumor Histologic Subtypes and Biomarkers.37231247Nelson BE, Reddy NK, Huse JT, Amini B, Nardo M, Gouda M, Weathers SP, Subbiah VNPJ precision oncologyHistological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma. NPJ Precis Oncol. 2023 May 25; 7(1):47.NPJ Precis Oncol2023-05-25T00:00:002023Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma.37295905Subbiah V, Pant SAnnals of oncology : official journal of the European Society for Medical OncologyTranslating immuno-onco-microbiome-based therapeutics: precision bugs for immune checkpoint drugs! Ann Oncol. 2023 06; 34(6):503-506.Ann Oncol2023-06-01T00:00:002023Translating immuno-onco-microbiome-based therapeutics: precision bugs for immune checkpoint drugs!37265425Subbiah V, Chawla SP, Conley AP, Wilky BA, Tolcher A, Lakhani NJ, Berz D, Andrianov V, Crago W, Holcomb M, Hussain A, Veldstra C, Kalabus J, O'Neill B, Senne L, Rowell E, Heidt AB, Willis KM, Eckelman BPClinical cancer research : an official journal of the American Association for Cancer ResearchPreclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma. Clin Cancer Res. 2023 08 15; 29(16):2988-3003.Clin Cancer Res2023-08-15T00:00:002023Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma.37270847Subbiah V, Sahai V, Maglic D, Bruderek K, Tour? BB, Zhao S, Valverde R, O'Hearn PJ, Moustakas DT, Sch?nherr H, Gerami-Moayed N, Taylor AM, Hudson BM, Houde DJ, Pal D, Foster L, Gunaydin H, Ayaz P, Sharon DA, Goyal L, Schram AM, Kamath S, Sherwin CA, Schmidt-Kittler O, Jen KY, Ricard F, Wolf BB, Shaw DE, Bergstrom DA, Watters J, Casaletto JBCancer discoveryRLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations. Cancer Discov. 2023 09 06; 13(9):2012-2031.Cancer Discov2023-09-06T00:00:002023RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations.Authorship 1075677937488229Mountzios G, Remon J, Hendriks LEL, Garc?a-Campelo R, Rolfo C, Van Schil P, Forde PM, Besse B, Subbiah V, Reck M, Soria JC, Peters SNature reviews. Clinical oncologyImmune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges. Nat Rev Clin Oncol. 2023 10; 20(10):664-677.Nat Rev Clin Oncol2023-07-24T00:00:002023Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges.Authorship 107823612Authorship 10790876Authorship 10781502Authorship 107817518Authorship 10795059Authorship 10783779Authorship 107784313Authorship 10790836Authorship 1078041237643131Denu RA, Moyers JT, Gouda MA, Conley AP, Lazar AJ, Subbiah VClinical cancer research : an official journal of the American Association for Cancer ResearchThe Landscape of Alterations from 1407 Ultra-Rare Sarcomas from the AACR GENIE Database: Clinical Implications. Clin Cancer Res. 2023 11 14; 29(22):4669-4678.Clin Cancer Res2023-11-14T00:00:002023The Landscape of Alterations from 1407 Ultra-Rare Sarcomas from the AACR GENIE Database: Clinical Implications.37736254Gouda MA, Janku F, Somaiah N, Hunt KK, Yedururi S, Subbiah VOncoscienceMulti-disciplinary management of recurrent gastrointestinal stromal tumor harboring KIT exon 11 mutation with the switch-control kinase inhibitor ripretinib and surgery. Oncoscience. 2023; 10:38-43.Oncoscience2023-09-20T00:00:002023Multi-disciplinary management of recurrent gastrointestinal stromal tumor harboring KIT exon 11 mutation with the switch-control kinase inhibitor ripretinib and surgery.37736255Gouda MA, Zarzour MA, Vaporciyan AA, Kairemo K, Chuang HH, Subbiah VOncoscienceActivity of pazopanib in EWSR1-NFATC2 translocation-associated bone sarcoma. Oncoscience. 2023; 10:44-53.Oncoscience2023-09-20T00:00:002023Activity of pazopanib in EWSR1-NFATC2 translocation-associated bone sarcoma.37517955Bhamidipati D, Subbiah VTrends in cancerTumor-agnostic drug development in dMMR/MSI-H solid tumors. Trends Cancer. 2023 10; 9(10):828-839.Trends Cancer2023-07-28T00:00:002023Tumor-agnostic drug development in dMMR/MSI-H solid tumors.37634282Leary A, Oaknin A, Trigo JM, Moreno V, Delord JP, Boni V, Bra?a I, Fern?ndez C, Kahatt C, Nieto A, Cullell-Young M, Zeaiter A, Subbiah VEuropean journal of cancer (Oxford, England : 1990)Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours. Eur J Cancer. 2023 10; 192:113259.Eur J Cancer2023-07-28T00:00:002023Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours.37574538Murray S, Subbiah V, Sherman SI, P?loquin S, Sireci A, Groh? C, Bubach P, Lazure PThyroid researchChallenges in the care of patients with RET-altered thyroid cancer: a multicountry mixed-methods study. Thyroid Res. 2023 Aug 14; 16(1):22.Thyroid Res2023-08-14T00:00:002023Challenges in the care of patients with RET-altered thyroid cancer: a multicountry mixed-methods study.37580188Fricke J, Wang J, Gallego N, Mambetsariev I, Kim P, Babikian R, Chen BT, Afkhami M, Subbiah V, Salgia RClinical lung cancerSelpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma: A Case Series. Clin Lung Cancer. 2023 11; 24(7):666-671.Clin Lung Cancer2023-08-06T00:00:002023Selpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma: A Case Series.37556023Kristeleit R, Leary A, Delord JP, Moreno V, Oaknin A, Castellano D, Shappiro GI, Fern?ndez C, Kahatt C, Alfaro V, Siguero M, Rueda D, Zeaiter A, Awada A, Santaballa A, Zaman K, Sehouli J, Subbiah VInvestigational new drugsLurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study. Invest New Drugs. 2023 10; 41(5):677-687.Invest New Drugs2023-08-09T00:00:002023Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study.37704501Boscolo Bielo L, Trapani D, Repetto M, Crimini E, Valenza C, Belli C, Criscitiello C, Marra A, Subbiah V, Curigliano GTrends in cancerVariant allele frequency: a decision-making tool in precision oncology? Trends Cancer. 2023 12; 9(12):1058-1068.Trends Cancer2023-09-12T00:00:002023Variant allele frequency: a decision-making tool in precision oncology?Authorship 10798292Authorship 108002616Authorship 10798001Authorship 1080079537757826Subbiah V, Verstovsek SCell reports. MedicineClinical development and management of adverse events associated with FGFR inhibitors. Cell Rep Med. 2023 10 17; 4(10):101204.Cell Rep Med2023-09-26T00:00:002023Clinical development and management of adverse events associated with FGFR inhibitors.37747813Denu RA, Yang RK, Lazar AJ, Patel SS, Lewis VO, Roszik J, Livingston JA, Wang WL, Shaw KR, Ratan R, Zarzour MA, Bird J, Raza S, Akdemir KC, Rodon Ahnert J, Subbiah V, Patel S, Conley APClinical cancer research : an official journal of the American Association for Cancer ResearchClinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes. Clin Cancer Res. 2023 12 01; 29(23):4844-4852.Clin Cancer Res2023-12-01T00:00:002023Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes.37760501Ravizzini G, Erwin W, De Palatis L, Martiniova L, Subbiah V, Paolillo V, Mitchell J, McCoy AP, Gonzalez J, Mawlawi OCancersDosimetry of a Novel 111Indium-Labeled Anti-P-Cadherin Monoclonal Antibody (FF-21101) in Non-Human Primates. Cancers (Basel). 2023 Sep 13; 15(18).Cancers (Basel)2023-09-13T00:00:002023Dosimetry of a Novel 111Indium-Labeled Anti-P-Cadherin Monoclonal Antibody (FF-21101) in Non-Human Primates.37769119Moyers JT, Subbiah VCancerTRKing sarcomas for precision medicine: Seek, and ye shall find! Cancer. 2023 12 01; 129(23):3694-3696.Cancer2023-09-28T00:00:002023TRKing sarcomas for precision medicine: Seek, and ye shall find!Authorship 1080382237779428Wu J, Subbiah VCancer researchRETooling the RET Inhibitor Pralsetinib for ESR1 Fusion-Positive Breast Cancer and Beyond. Cancer Res. 2023 10 02; 83(19):3159-3161.Cancer Res2023-10-02T00:00:002023RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion-Positive Breast Cancer and Beyond.Authorship 1082453337916501Griesinger F, Curigliano G, Subbiah V, Baik CS, Tan DS, Lee DH, Misch D, Garralda E, Kim DW, van der Wekken AJ, Gainor JF, Paz-Ares L, Liu SV, Kalemkerian GP, Bowles DW, Mansfield AS, Lin JJ, Smoljanovic V, Rahman A, Zalutskaya A, Louie-Gao M, Boral AL, Mazi?res JFuture oncology (London, England)Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW study. Future Oncol. 2024 Feb; 20(6):297-306.Future Oncol2023-11-02T00:00:002023Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW study.Authorship 10832581Authorship 10832571337933916Griesinger F, Ramagopalan S, Cheung WY, Wilke T, Mueller S, Gupta A, O'Sullivan DE, Arora P, Brenner DR, Froelich C, Inskip J, Maywald U, Subbiah VCancerAssociation between treatment and improvements in overall survival of patients with advanced/metastatic non-small cell lung cancer since 2011: A study in the United States, Canada, and Germany using retrospective real-world databases. Cancer. 2024 02 15; 130(4):530-540.Cancer2023-11-07T00:00:002023Association between treatment and improvements in overall survival of patients with advanced/metastatic non-small cell lung cancer since 2011: A study in the United States, Canada, and Germany using retrospective real-world databases.37934000Subbiah V, Burris HA, Kurzrock RCancerRevolutionizing cancer drug development: Harnessing the potential of basket trials. Cancer. 2024 01; 130(2):186-200.Cancer2023-11-07T00:00:002023Revolutionizing cancer drug development: Harnessing the potential of basket trials.Authorship 108465630Authorship 10842261Authorship 1083789638009200Subbiah V, Hu MI, Mansfield AS, Taylor MH, Schuler M, Zhu VW, Hadoux J, Curigliano G, Wirth L, Gainor JF, Alonso G, Adkins D, Godbert Y, Ahn MJ, Cassier PA, Cho BC, Lin CC, Zalutskaya A, Barata T, Trask P, Scalori A, Bordogna W, Heinzmann S, Brose MSThyroid : official journal of the American Thyroid AssociationPralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study. Thyroid. 2024 01; 34(1):26-40.Thyroid2024-01-01T00:00:002024Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.38060240Kasi PM, Lee JK, Pasquina LW, Decker B, Vanden Borre P, Pavlick DC, Allen JM, Parachoniak C, Quintanilha JCF, Graf RP, Schrock AB, Oxnard GR, Lovly CM, Tukachinsky H, Subbiah VClinical cancer research : an official journal of the American Association for Cancer ResearchCirculating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types. Clin Cancer Res. 2024 02 16; 30(4):836-848.Clin Cancer Res2024-02-16T00:00:002024Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types.38039431Bhamidipati D, Yedururi S, Huse J, Chinapuvvula SV, Wu J, Subbiah VJCO precision oncologyExceptional Responses to Selpercatinib in RET Fusion-Driven Metastatic Pancreatic Cancer. JCO Precis Oncol. 2023 Sep; 7:e2300252.JCO Precis Oncol2023-09-01T00:00:002023Exceptional Responses to Selpercatinib in RET Fusion-Driven Metastatic Pancreatic Cancer.Authorship 10856311Authorship 10856021038126764Subbiah V, Coleman N, Piha-Paul SA, Tsimberidou AM, Janku F, Rodon J, Pant S, Dumbrava EEI, Fu S, Hong DS, Zhang S, Sun M, Jiang Y, Roszik J, Song J, Yuan Y, Meric-Bernstam F, Naing ACancer research communicationsPhase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies. Cancer Res Commun. 2024 02 12; 4(2):378-387.Cancer Res Commun2024-02-12T00:00:002024Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.38118420Nardo M, Gouda MA, Nelson BE, Barreto CMN, Slade JH, Poullard A, Zafereo M, Hu MI, Cabanillas ME, Subbiah VCell reports. MedicineStrategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers. Cell Rep Med. 2023 12 19; 4(12):101332.Cell Rep Med2023-12-19T00:00:002023Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers.Authorship 10866731538198859Peters S, Trigo J, Besse B, Moreno V, Navarro A, Eugenia Olmedo M, Paz-Ares L, Groh? C, Antonio Lopez-Vilari?o J, Fern?ndez C, Kahatt C, Alfaro V, Nieto A, Zeaiter A, Subbiah VLung cancer (Amsterdam, Netherlands)Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval =30 days and without central nervous metastases. Lung Cancer. 2024 02; 188:107448.Lung Cancer2023-12-27T00:00:002023Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval =30 days and without central nervous metastases.Authorship 1087585538245379Ahluwalia MS, Khosla AA, Ozair A, Gouda MA, Subbiah VTrends in cancerImpact of tissue-agnostic approvals on management of primary brain tumors. Trends Cancer. 2024 Mar; 10(3):256-274.Trends Cancer2024-01-19T00:00:002024Impact of tissue-agnostic approvals on management of primary brain tumors.Authorship 1088109238298151Nelson BE, Subbiah VMolecular cancer therapeuticsPredicting the Abscopal Phenomenon-Reply. Mol Cancer Ther. 2024 Feb 01; 23(2):250.Mol Cancer Ther2024-02-01T00:00:002024Predicting the Abscopal Phenomenon-Reply.Authorship 1088926238358775Beg MS, Subbiah VJAMA oncologyModernize Precision Oncology With Decentralized Trial Tools. JAMA Oncol. 2024 Feb 15.JAMA Oncol2024-02-15T00:00:002024Modernize Precision Oncology With Decentralized Trial Tools.Authorship 10892143Authorship 1089409538400671Coleman N, Stephen B, Fu S, Karp D, Subbiah V, Ahnert JR, Piha-Paul SA, Wright J, Fessahaye SN, Ouyang F, Yilmaz B, Meric-Bernstam F, Naing ACancer medicinePhase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors. Cancer Med. 2024 Feb; 13(3):e6877.Cancer Med2024-02-01T00:00:002024Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors.38380848Bhamidipati D, Pellatt A, Subbiah VJCO precision oncologyTargeting All BRAF Alterations: The (Re)-Search Continues. JCO Precis Oncol. 2024 Feb; 8:e2300670.JCO Precis Oncol2024-02-01T00:00:002024Targeting All BRAF Alterations: The (Re)-Search Continues.Authorship 1089720238401908Gouda MA, Subbiah VSurgical oncology clinics of North AmericaTissue-Agnostic Cancer Therapy Approvals. Surg Oncol Clin N Am. 2024 Apr; 33(2):243-264.Surg Oncol Clin N Am2023-12-26T00:00:002023Tissue-Agnostic Cancer Therapy Approvals.Authorship 1090229138438731Subbiah V, Gouda MA, Iorgulescu JB, Dadu R, Patel K, Sherman S, Cabanillas M, Hu M, Castellanos LE, Amini B, Meric-Bernstam F, Shen T, Wu JNPJ precision oncologyAdaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer. NPJ Precis Oncol. 2024 Mar 04; 8(1):62.NPJ Precis Oncol2024-03-04T00:00:002024Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer.Authorship 1091284238502426Nesline MK, Subbiah V, Previs RA, Strickland KC, Ko H, DePietro P, Biorn MD, Cooper M, Wu N, Conroy J, Pabla S, Zhang S, Wallen ZD, Sathyan P, Saini K, Eisenberg M, Caveney B, Severson EA, Ramkissoon SOncology and therapyThe Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer. Oncol Ther. 2024 Mar 19.Oncol Ther2024-03-19T00:00:002024The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer.true1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1Assistant ProfessorAssistant Professortrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessor